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SUMMARY
I isolated and characterised a clone of the normal feline c-myc
gene. Sequence analysis showed the gene to be highly related in other
mammals but less well related in the chicken. The feline c-myc gene 
possessed an apparently non-coding first exon with a dual promoter 
structure, similar to that found in the human and mouse c-myc genes.
The sequences of three independent FeLV v-myc genes were compared to
that of the c-myc gene to identify possible structural alterations 
involved in myc oncogenic activation. The c-myc clone also provided 
probes to map c-myc rearrangements in feline thymic lymphosarcomas. 
Some rearrangements were due to FeLV integration within or upstream of 
c-myc, but one case involved a complex 3' alteration which was 
apparently not directly virus-induced.
81 nuclease mapping of RNA from normal cells using c-myc probes 
located 5' discontinuities to each of the two promoter-like sequences 
(PI and P2), and a major 3' discontinuity mapping to the most 3' of two 
possible pcJ^adenylation signals. Tumours carrying c-myc rearrangements 
did not display readily obvious abnormalities in the structure or 
levels of c-myc RNA, except for case T24 which appeared to contain RNA 
lacking exon 1 sequences. However, the ratio of PI to P2 RNAs detected 
in tumours varied considerably and was high in tumours with a 
rearrangement adjacent to c-myc, although it was equally high in some 
tumours with an ostensibly normal c-myc gene structure. There was a 
consistent lack of detectable RNA from normal c-myc alleles in tumours 
containing different myc-transducing FeLVs. Also, in tumour T24 which 
expressed a rearranged c-myc gene, RNA from the normal c-myc allele 
could not be detected.
The phenotype of thymic tumours was characterised with respect to 
expression of RNA of the a  and ^-chains of the T-cell antigen receptor 
(TCR). Several tumours, including all those induced by two 
myc-transducing FeLVs and others carrying a rearranged c-myc gene, 
contained TCR a  and (3-chain transcripts. This study provided 
preliminary evidence that one tumour contained independently transduced 
myc and P-chain TCR genes present in separate FeLV proviruses, 
suggesting a direct role for TCR genes in oncogenesis.
CHAPTER ONE 
GENERAL INTRODUCTION
Feline leukaemia virus (FeLV) is a retrovirus and is an important 
pathogen of the domestic cat. Infection can result in a variety of 
diseases including degenerative and proliferative conditions (Jarrett, 
1984). This thesis concerns the molecular mechanisms by which FeLV 
induces leukaemias, especially thymic lymphosarcomas, the most common 
neoplasm associated with the virus. The introduction first considers 
some mechanisms of oncogenesis by retroviruses, then outlines features 
of FeLV pathogenesis. Finally, I discuss the myc gene since much of my 
work concerns the involvement of this gene in feline leukaemias.
1.1 THEORIES OF ONCOGENESIS
1.1.1 General
There have been various theories concerning mechanisms of 
oncogenesis. The somatic mutation hypothesis of Boveri in 1914 proposed 
that normal cells became transformed due to genetic changes associated 
with chromosomal abnormalities (Ruddon, 1981). This idea has gained 
support through cytogenetic analysis showing that many tumours display 
characteristic chromosomal rearrangements (Rowley, 1984). Further 
support for a genetic basis for cancer has been provided by study of 
tumours induced by chemical carcinogens which have been associated with 
mutations in specific cellular genes (Barbacid, 1985). Alternative 
evidence linking genetic changes with neoplasia was provided by 
observations that susceptibility to some human tumours, such as 
retinoblastoma, could be associated with inherited genetic defects 
(Knudsen, 1971).
Different views have held that oncogenic mutations may activate a 
dominant transforming gene or alternatively inactivate some suppressor 
function to release cells from normal growth restraints (Murphree & 
Benedict, 1984). However, mutational theories of cancer do not have 
unanimous support and another perspective has been that epigenetic 
factors rather than mutations contribute to cancer development (Rubin, 
1980).
1.1.2 Retroviruses and oncogenesis
Viruses have been implicated as causal agents in tumours since
Ellerman and Bang in 1908 and Rous in 1911 showed that cell-free 
extracts from chicken leukaemias and sarcomas could transmit these 
diseases. These and similar studies with mouse mammary tumours and 
leukaemias led to the identification of retroviruses as oncogenic 
agents (Weiss et al, 1985). In 1964, transmission of feline 
lymphosarcoma with cell-free extracts led to the discovery of feline 
leukaemia virus (Jarrett et al, 1964).
Detailed molecular theories of retrovirus-induced oncogenesis have 
developed only relatively recently as the integrative replication-cycle 
of these RNA tumour viruses has been understood. Early ideas focused on 
genetic mechanisms whereby expression of viral genes was necessary for 
transformation. An aspect of the "protovirus hypothesis" of Temin 
(1976) was that an acutely oncogenic virus incorporated a cell-derived 
cancer gene by recombination. An alternative view was the "oncogene 
hypothesis" of Huebner & Todaro (1959). They proposed that many 
vertebrates contained endogenous viruses or "virogenes" which included 
an "oncogene" sequence. Normally these genes would be suppressed but 
carcinogenic agents might derepress their expression. Some elements of 
both hypotheses proved correct as a wealth of recent evidence showed 
that some, but by no means all, oncogenic retroviruses carry specific 
transforming genes, or oncogenes (section 1.2).
1.1.3 Multistep oncogenesis
Recognition that retroviral oncogenes, or v-onc genes, were modified 
versions of normal cellular genes (proto-oncogenes) (Bishop, 1983) 
provided a link between viral and non-viral theories of oncogenesis, 
since it was apparent that the transforming potential of a 
proto-oncogene might be activated by different agents including 
viruses, chemical carcinogens or chromosomal abnormalities. Tumour 
development has been viewed as a multistep process based on genetic and 
epidemiological observations and experimental studies with chemical 
carcinogens (Ashley, 1969; Knudsen, 1971). The discovery and functional 
study of oncogenes suggested possible molecular events underlying these 
stepwise phenotypic changes (Klein & Klein, 1985). However, evidence 
for epigenetic mechanisms in oncogenesis suggested that the 
contributory events need not all be mutational changes, and the 
cellular environment and host's physiological status may also play a 
part (Rubin, 1980; Barbacid, 1986).
1.2 RETROVIRAL ONCOGENES
1.2.1 The src gene
The first v-onc gene to be discovered was the src gene of Rous 
sarcoma virus (RSV) which illustrates some general features of other 
v-onc genes. Study of RSV mutants by Toyoshima & Vogt (1969) and Martin 
(1970) showed the RSV transforming gene to be distinct from the viral 
replicative genes and that its continuous expression was required to 
maintain the transformed state. After physical characterisation of the 
gene, called src, use of a src-specific hybridisation probe yielded the 
remarkable finding that normal, uninfected chicken DNA contained a 
src-related gene (Stehelin et al, 1976). Other vertebrates were also 
found to contain a src-related gene.
More than twenty v-onc genes have now been identified in avian, 
murine, feline and simian retroviruses and a general property seems to 
be that related genes (c-onc genes) are present in normal DNA from 
diverse species (Bishop, 1985 ). This finding had important 
implications as discussed below. However, it should be mentioned that 
not all retroviral oncogenes need fit this category. One example seems 
to be that induction of murine erythroleukaemia by SFFV requires 
expression of an unusual viral recombinant env product rather than a 
cell-derived sequence (Linemeyer et al, 1982).
1.2.2 The origin of viral oncogenes
The relationship of v-onc genes to normal cellular genes suggested
that a v-onc gene was a captured version of a c-onc gene as predicted
by Temin's protovirus hypothesis. Models for the capture of cellular
sequences by retroviruses have been based on structural comparison of
S^Varmuf
V-onc and proto-oncogene sequences (Bishop, 1985 ). The structure of 
most viral oncogenes is consistent with the model of Swanstrom et al 
(1983) for transduction of the src gene by RSV. This proposes that 
initial recombination occurs at the DNA level as a result of proviral 
integration. The provirus integrates 5' to the gene to be transduced, 
then a deletion leads to generation of viral-cellular gene fusion 
transcripts, which may be spliced and packaged into virus particles. A 
second recombination step between this RNA and an intact viral RNA 
genome would provide the 3' end of the recombinant viral genome. The 
absence of introns from v-onc genes and the presence of a poly(A) tail
at the 3' end of a v-fps gene support the involvement of an RNA 
intermediate (Huang et al, 1985).
This need not be the only possible mechanism, and another model 
considered the formation of oncogenic retroviruses from cellular 
movable genetic elements (Temin, 1980). Interestingly, the v-ski gene 
of SK virus is flanked by small direct repeats similar to those 
occurring at each end of inserted transposable elements (van Beveren et 
al, 1985).
1.2.3 The role of cellular oncogenes
The wide occurrence of genes related to v-onc genes in different 
species agreed in some ways with the oncogene hypothesis of Huebner & 
Todaro. But contrary to their hypothesis, c-onc genes normally were not 
associated with viruses and were expressed in normal cells, presumably 
performing some fundamental function in diverse species.
Some progress has been made in understanding the function of v- and 
c-onc genes. A major theme links many genes with different stages of 
cellular growth control networks (Weinberg, 1985). Several src-related 
products (e.g. abl, erbB, fms) display tyrosine kinase activity and 
include products related to known growth factor receptors. Their 
potential role in transmitting external growth signals into the cell is 
supported by their location at the plasma membrane.
The ras family products may act a similar level as they are related 
to G proteins which are involved in control of growth signal 
transmission from the plasma membrane into the cell (review; Lowy & 
Willumsen, 1986). In contrast, the sis product may function as a growth 
factor itself, as it is secreted and is homologous to PDGF (Heldin & 
Westermark, 1984). A distinct group of oncogenes are those coding for 
products which are located in the nucleus (myc, myb, fos; Eisenman & 
Thompson, 1986) leading to speculation that they may control expression 
of other genes.
1.2.4 Non-viral activation of oncogenes
The presence of proto-oncogenes in normal cells presented the 
possibility that they may be activated by means other than viral 
transduction. Direct evidence that tumours may contain active oncogenes 
which were not associated with viruses was obtained using fibroblast 
transformation assays with tumour DNA (review: Lowy & Willumsen, 1986). 
This identified transforming c-ras genes, activated by specific point
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mutations. These genes were the cellular homologues of the v-ras genes 
of murine sarcoma viruses.
Indirect evidence implied that the oncogenic potential of other 
c-onc genes could be activated by non-viral mechanisms. The c-myc gene, 
the counterpart of the MC29 virus v-myc gene, was found frequently to 
be disrupted by characteristic chromosomal translocations in Burkitt's 
lymphomas (review: Leder et al, 1983). Similarly, the c-abl gene,
homologue of the v-abl gene of Abelson-MuLV, was altered on the 
rearranged Philadelphia chromosome in human myeloid leukaemias (review: 
Adams, 1985). Another mode of rearrangement of c-onc genes was 
amplification, as found for example, with the c-myc gene in various 
human tumours (section 1.6).
1.2.5 Alterations in structure and expression of oncogene products
Transforming genes have been proposed to differ from their normal 
counterparts by inappropriate expression or by coding changes giving a 
malfunctioning product. Thus, v-onc genes are highly expressed compared 
to their normal c-onc progenitors. On the other hand transforming c-ras 
genes become active through specific point mutations (Lowy & Willumsen, 
1986). However, this may be an artificial division, since both factors 
may be required for oncogenic activation of some genes.
Studies on the v-src gene of one strain of RSV show that coding
changes and elevated expression contribute in this case. It was shown 
that the gene must be expressed at a threshold level to achieve
transformation (Jakobovits et al, 1984). However, over-expression of 
the normal c-src gene did not cause transformation, suggesting that 
some structural change was also necessary. This v-src gene carried an 
altered C-terminus coding region and multiple codon changes relative to 
c-src, but only a single amino acid substitution was required to 
confer transforming activity if the product was expressed at elevated 
levels (Levy et al, 1986).
1.3 CIS-ACTIVATION OF CELLULAR ONCOGENES BY PROVIRUSES
1.3.1 General
Many retroviruses which do not appear to carry an oncogene have been 
classed as weakly oncogenic since in general they do not transform
cells vitro and induce tumours with long latency vivo. Tumours of
chickens, mice and cats induced by these viruses often display a clonal
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pattern of integrated proviruses, indicating that they derive from one 
or a few infected cells (Payne et al, 1981; Fung et al, 1981; Cohen et 
al, 1979; van der Putten et al, 1979; Casey et al, 1981). This led to 
proposal of the model of insertional mutagenesis whereby an integrated 
provirus activates the transforming potential of an adjacent c-onc gene 
in a cell which then proliferates to form a clonal tumour. This 
concept was first supported by Hayward, Neel and Astrin (1981) who 
showed that proviruses were inserted at the c-myc locus in ALV-induced 
chicken bursal lymphomas.
Many target genes for proviral insertions have now been identified 
in tumours in different species, by two main approaches. First, some 
tumours were found to carry insertions at c-onc homologues of known 
v-onc genes, such as c-erbB in chicken erythroleukaemias, c-myb in 
mouse lymphoid tumours and c-Ha-ras in a chicken nephroblastoma (Fung 
et al, 1983; Shen-Ong et al, 1985; Westaway et al, 1986). Also, 
insertions have been found at loci coding for the known growth factors 
IL-2 and IL-3 in leukaemic cell lines of the ape and mouse 
respectively (Chen et al, 1985; Ymer et al, 1985).
Secondly, tumour-specific, common integration sites have been 
characterised with the expectation that they might represent previously 
unknown genes with oncogenic potential. This was based on the 
assumption that proviral integration would not normally occur at 
specific host sites (Nusse, 1986). Thus, detection of a common 
integration site in tumours may indicate clonal expansion of a cell 
which sustained an oncogenic insertion.
This has revealed several novel putative oncogenes. In MuLV-induced 
thymic lymphomas, the pim-1 and Mlvi loci were frequently found to 
carry proviral insertions in the mouse and rat respectively (Cuypers et 
al, 1984; Tsichlis et al, 1983), and in MMTV-induced mammary carcinomas 
the int-1 and int-2 loci were often disrupted (Nusse & Varmus, 1982; 
Peters et al, 1983).
Recently, it has been shown that an int-1 gene construct partly 
transforms epithelial cells, providing experimental evidence that 
cellular genes identified in this way have transforming function (Brown 
et al, 1986). Also, the pim-1 sequence indicates that it is related to 
the protein kinase gene family which includes several known oncogenes 
(Selten et al, 1986).
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1.3.2 Mechanisms of cis-activation
The role of a provirus as an insertional mutagen generally depends 
on its powerful LTR transcriptional controls which deregulate 
expression of the adjacent c-onc gene. Additional genetic changes have 
been reported, such as alteration of the c-onc coding sequence, 
amplification of the rearranged allele or insertions at other loci. 
These observations suggested that an oncogenic insertion may initiate 
cell transformation and other genetic changes may contribute to tumour 
progression.
Promoter insertion. ALV insertions at the 5' end of c-myc often are 
in the same transcriptional direction as the gene, and generate 
ALV-c-myc fusion transcripts initiated in the 3' LTR U5 region 
(Hayward et al, 1981; Payne et al, 1982). A variation of this theme 
produces fusion transcripts initiating in the proviral 5' LTR which are 
spliced onto c-onc gene exons from a viral splice donor signal, as 
found with ALV insertions at c-erbB and MuLV insertions at c-myb 
(Raines et al, 1985; Shen-Ong et al, 1985).
Enhancer insertion. Some ALV proviruses were found to be 3' to the 
c-myc gene or upstream and in the opposite orientation, and so could 
not direct c-myc transcription from viral promoters (Payne et al,
1982). In the mouse, similar modes of insertion have been found to be 
common for MuLV proviruses at the c-myc locus in thymic lymphomas 
(Corcoran et al, 1984; Selten et al, 1984), and for MMTV proviruses at 
the int-1 and -2 loci in mammary tumours (Nusse et al, 1984; Dickson et 
al, 1984). These findings suggested that enhancers in the proviral LTRs 
acting independently of orientation, could superimpose viral control of 
transcription from the normal cellular gene promoters.
Alteration of the product. Some insertions, such as ZAP genes at the 
c-mos gene in murine plasmacytomas, or ALV proviruses at the c-erbB 
gene in chicken erythroleukaemias are within the coding domain of the 
c-onc gene suggesting that product truncation may be required for 
activation (Cohen et al, 1983; Nilsen et al, 1985). Also, point 
mutations have been detected in the coding region of a c-myc gene 
carrying an upstream ALV insertion (Westaway et al, 1984).
Amplification of the rearranged locus. It was found that some c-myc 
loci which carry REV or MuLV insertions were amplified to a small 
extent (Noori-Daloii et al, 1981; Li et al, 1984; Cuypers et al, 1986).
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For mouse tumours, this appears to be due to duplication of the 
chromosome carrying the MuLV insertion (Cuypers et al, 1986).
Multiple insertions at different loci. There are a few examples of 
independent insertions at different cellular loci with oncogenic 
potential in the same tumour cell clone. These include MuLV proviruses 
at the c-myc and pim-1 loci (Selten et al, 1985) or at the Mlvi-1 and 
-2 loci (Tsichlis et al, 1985), or MMTV proviruses at the int-1 and -2 
loci (Peters et al, 1986).
1.4 OTHER THEORIES OF RETROVIRUS-INDUCED ONCOGENESIS
Cell-derived oncogenes have not been found to be directly involved 
in all retrovirus-associated tumours, and some other oncogenic 
mechanisms have been proposed, as briefly outlined in the following:
1.4.1 Immunosuppression
Retroviral infection may be immunosuppressive to the host (Enrietto 
& Wyke, 1983; Jarrett, 1984). For example, young cats infected with 
FeLV often display immunosuppression and thymic atrophy (Anderson et
al, 1971). This condition also precedes experimental induction of
thymic lymphosarcoma by FeLV, suggesting that it predisposes the cat to 
neoplastic disease. One speculation might be that as the host produces 
more cells to compensate for lymphoid cell depletion there is an
increased probability of occurrence of oncogenic mutations.
1.4.2 Chronic immunostimulation
In the mouse, the chronic immunostimulation theory of 
leukaemogenesis proposes that MuLV viraemia is essential to cause a 
chronic cellular immune repense which is an important preceding step in 
T-cell leukaemogenesis (Ihle & Lee, 1982). This is thought to be 
mediated by production of interleukins by infected cells. The expanding 
pool of T-cells may be prone to acquiring oncogenic mutations perhaps 
by proviral insertions or other events.
1.4.3 Oncogenic potential of viral replicative genes
Viral replicative genes distinct from cell-derived oncogenes also 
may interfere with host cell growth. McGrath et al (1980) have proposed 
a model of receptor-mediated leukaemogenesis for murine thymic 
lymphomas where mitogenic stimulation of MuLV-infected T-cells occurs 
through binding of viral env products to specific antigen receptors. 
This model may apply to any retrovirus-associated lymphoma where the
14
tumour cells express functional antigen receptors.
Study of human T-lymphotropic viruses (HTLV-I and -II) and bovine 
leukaemia virus (BLV) has revealed the trar^-activating tat genes, 
unrelated to previously known viral replicative genes, which augment 
viral transcription or the stability of viral transcripts through 
responsive elements in the LTR (Chen et al, 1986). A leukaemogenic role 
for tat genes has been proposed by Greene et al (1986) who presented
evidence that tat products stimulate expression of the cellular IL-2
and IL-2 receptor genes, perhaps through control elements related to
those in the viral LTR.
1.5 FeLV PATHOGENESIS
1.5.1 Infection
FeLV infects domestic cats and so provides an opportunity to study 
the role of a leukaemogenic retrovirus in naturally-occurring tumours. 
In 1973, it was demonstrated that FeLV can be transmitted 
horizontally, showing that retroviruses may be important agents of 
disease in an outbred population ( Mo-rdl^  et al, 1973). Transmission is 
usually horizontal through body fluids of infected cats, and may be 
congenital by virus transfer across the uterus to the embryo (Jarrett,
1984). Persistently viraemic cats show a high incidence of FeLV-related 
disease, although the outcome of infection depends on various factors 
such as virus dose and host age (Jarrett, 1984). A young cat 
encountering a high dose of virus is most susceptible whereas older 
cats are more resistant.
1.5.2 Neoplastic diseases
Spontaneous neoplastic diseases of the cat often involve 
haemopoietic tissue, and most are lymphoid in origin (Jarrett, 1984). 
The common tumours include thymic or multicentric lymphosarcomas which 
are usually virus-positive, and alimentary lymphosarcomas of which only 
one third are virus-positive. Some other forms of leukaemia may be 
under-diagnosed.
Experimental study of thymic lymphosarcoma development using the 
FeLV Rickard strain (Rickard et al, 1969) reveals early thymic atrophy 
followed by infiltration of the thymic remnant with malignant 
lymphocytes of unknown origin, which proliferate to form the tumour.
15
1.5.3 FeLV sub-groups
FeLV isolates may be grouped as sub-group A, B or C depending on 
properties of their envelope glycoproteins. FeLV-B and -C occur in 
nature only in association with FeLV-A which may reflect dependence on 
FeLV-A for transmission (Jarrett et al, 1978). FeLV-B and -C env genes 
are thought to result from recombination between a parental FeLV-A and 
endogenous proviral sequences (Stewart et al, 1986a; Neil & Onions,
1985). Different sub-groups may be associated with particular diseases, 
which may be due to different target cell preferences (Onions et al,
1982). Interestingly, FeLV-AB mixes may have a greater capacity to 
induce thymic lymphosarcoma than does FeLV-A alone (Jarrett, 1984).
1.5.4 Oncogenic mechanisms of FeLV
Direct oncogenic mechanisms involving FeLV include transduction and 
insertional mutagenesis of cellular oncogenes. Study of 
naturally-occurring feline tumours has revealed many examples of 
oncogene transduction by FeLV (Table 1.1). Initial studies focused on 
the feline sarcoma viruses, isolated from rare cases of multicentric 
fibrosarcoma in young cats, which were found to carry a variety of 
oncogenes (Besmer, 1983). Many of these v-onc genes were related to the 
tyrosine kinase gene family, but also included the sis and K-ras genes. 
Many of these viruses have been shown to induce sarcomas rapidly in 
young cats and to transform cells in culture.
However, in thymic lymphosarcomas, the most common tumour type 
associated with FeLV infection, it was more recently found that there 
is a relatively high incidence (~25%) of transduction of the myc gene 
(Neil et al, 1984; Levy et al, 1984; Mullins et al, 1984). This 
finding was important since it provided the first example of 
transduction of the mammalian myc gene, with v-myc genes previously 
only known in avian retroviruses. Secondly, since most of the tumours 
examined were field cases, it indicated that transduction may be more 
frequent in naturally-occurring tumours than commonly believed (Bishop,
1983). It also included T-cell lymphomas within the range of tumours 
associated with myc alterations; previously the gene was mainly 
associated with B-cell lymphomas of the chicken, man and mouse, and 
with various chicken leukaemias and carcinomas. Although FeLV/myc 
viruses have not been found to transform cells in culture, they induce 
thymic tumours with short latency in young cats (Neil et al, 1984; D.
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Onions, G. Lees, D. Forrest & J. Neil, Int. J. Cancer, in press).
Apart from myc transduction, several field case and experimental 
lymphosarcomas showed alteration of the c-myc locus by proviral 
insertion, amplification or other rearrangement (Neil et al, 1984; D. 
Forrest et al, submitted; J. Mullins, pers. comm.). In 
experimentally-induced tumours, proviral insertions occur at a similar 
high frequency (>50%) to that recorded in MuLV-induced thymic lymphomas 
of the mouse (Selten et al, 1984; O'Donnell et al, 1985).
A detailed study of the normal and altered myc genes in feline 
leukaemias is the main subject of this thesis, and so a brief review 
concerning the normal and oncogenic roles of the myc gene now follows.
1.6 THE c-myc GENE
1.6.1 General
The c-myc gene probably has a critical role in control of normal and 
tumour cell growth, although its precise function remains unknown at 
present. First, since the gene is highly related between species (van 
Beveren et al, 1985) it is presumed to play a fundamental role. 
Secondly, c-myc expression generally correlates with growth of various 
cell types (see below) and appears to be subject to complex controls, 
suggesting that the gene serves a critical role requiring fine 
regulation (Saito et al, 1983; Dani et al 1984; Remmers et al, 1986; 
Bentley & Groudine, 1986a). Thirdly, alteration of the gene by diverse 
mechanisms has been associated with a variety of tumours (Table 1.2). 
This implies that the gene has a crucial role in normal growth control 
and is an important target in oncogenesis.
1.6.2 The c-myc gene in cell growth
Expression of the c-myc gene is seen in many normal and tumour 
tissues (Gonda et al, 1982; Slamon et al, 1984). Generally, expression 
correlates with growth, being induced upon mitogenic stimulation of 
resting normal cells and tissue (Kelly et al, 1983; Makino et al,
1984), and down-regulated during growth inhibition of haemopoietic and 
other cells (Reitsma et al, 1983; Lachman & Skoultchi, 1984; Campisi et 
al, 1984). In growing cells, c-myc RNA and protein are expressed 
continuously throughout the cell cycle (Thompson et al, 1985; Hann et 
al, 1985).
The myc product may enable cells to enter and progress through the 
cell-cycle. Resting B^LB/c 3T3 fibroblasts require "competence" factors
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such as PDGF to become sensitive to later-acting factors such as 
epidermal growth factor, which are necessary for progression through 
DNA synthesis and mitosis (Stiles et al, 1979). Direct evidence that 
c-myc is a competence factor comes from micro-injection of the c-myc 
protein into the nuclei of fibroblasts which promotes DNA synthesis 
without requiring PDGF (Kaczmarek et al, 1985).
It is of interest in studying the myc gene in feline T-cell tumours 
that similar events occur in lymphoid cell growth. Stimulation of 
resting lymphocytes with mitogens, or specific stimulation of the 
T-cell antigen receptor (TCR) by monoclonal antibody rapidly induces 
c-myc expression (Kelly et al, 1983; Reed et al, 1985). Normally, 
proliferation of mature T-cells in the immune response responds to 
antigenic stimulation mediated by the TCR, analogously to fibroblast 
proliferation through growth factor receptors (Smith, 1985). 
Immunostimulation of T-cells induces an IL-2 responsive state for IL-2 
dependent DNA synthesis and mitosis (Waldman, 1986). Hence, c-myc 
expression may be a common factor which primes T-cells and fibroblasts 
for growth.
How might the myc product mediate growth control? The myc product 
was found to be located in the nucleus which suggested a possible role 
in interaction with nucleic acids, possibly in controlling expression 
of other genes. In vitro studies showed that the myc product binds DNA 
(Bunte et al, 1984; Watt et al, 1985), perhaps a function of the 
C-terminus which is rich in basic amino acids. Whether DNA binding 
occurs vivo is not known, but a possible role for c-myc in
controlling gene expression iu trans was shown by co-transfection 
studies with genes under control of heat shock gene promoters (Kingston 
et al, 1984).
1.6.3 Oncogenic potential
The oncogenic activity of the myc gene is known principally from 
study of avian myc-transducing viruses which induce a range of 
carcinomas and leukaemias in chickens (Hayman, 1983). Recent studies 
have shown that myc-transducing FeLVs rapidly induce thymic 
lymphosarcomas in cats (D. Onions et al, in press).
There is some evidence that rearranged c-myc genes may have 
transforming potential, based on introduction of c-myc constructs into 
cells in culture or into transgenic mice. In summary, the in vitro
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studies indicate that the gene may not always be active on its own in 
transforming fibroblasts, but it does transform efficiently in 
cooperation with ras genes (Keath et al, 1984; Lee et al, 1985; Martin 
et al, 1985). Experiments with transgenic mice show that tumours 
reproducibly arise in tissues in which the c-myc construct is expressed 
(Stewart et al, 1984b; Adams et al, 1985).
In almost all tumours in which a rearranged c-myc gene has been
identified, it remains to be demonstrated that the gene has
transforming activity. However, since v-myc genes and c-myc constructs 
display transforming activity, then by inference c-myc rearrangements 
may have had a similar role in the tumours in which they were
identified. The frequency of c-myc rearrangement in tumour development 
may also support this view. For example, > 80% of ALV-induced chicken 
bursal lymphomas carry a proviral insertion and most human Burkitt's 
lymphomas carry a chromosomal translocation breakpoint at the c-myc
locus (Crittenden & Kung,1984; Leder et al, 1983).
1.7 EXPERIMENTAL OUTLINE
I began my study a short time after the discovery that the myc gene 
was either transduced by FeLV or otherwise rearranged in a subset of 
feline leukaemias (Neil et al, 1984; Levy et al, 1984; Mullins et 
al,1984). This finding prompted two main lines of research in Glasgow 
into the molecular mechanisms underlying feline leukaemias. First, what 
are the mechanisms of alteration of the myc gene in tumours? Secondly, 
since the myc gene was only implicated in 30% of tumours, what other 
events may be involved?
My work involved isolation and characterisation of a clone of the 
normal feline c-myc gene. This was necessary since it was not known how 
the feline gene compared with that in other species. Also, analysis of 
the sequence of the c-myc gene was. essential for investigation of 
possible structural changes present in FeLV v-myc genes (Chapter 3). 
Determination of the normal c-myc gene structure also permitted 
detailed mapping by Southern blot hybridisation analysis of 
rearrangements of the c-myc gene in other tumours, since little was 
known of the nature of these alterations (Chapter 4).
It was also important to study, by Northern blot and 81 nuclease 
analysis, expression of the normal, rearranged and transduced myc genes
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to understand the consequences of structural alteration (Chapters 5 and 
6).
Finally, the available tumours were characterised with respect to 
expression of transcripts of the T-cell antigen receptor to provide 
clues to other events important in development of these leukaemias 
(Chapter 7).
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Cellular gene Associated disease Number of Refs, 
isolates
fes
fms
abl
sis
kit
fgr + actin 
K-ras
m £
ter
fibrosarcoma
lymphosarcoma
1
1,2
1
1
3
4 
1
5,6
6
Table 1.1. Cellular genes transduced by feline retroviruses.
Refs. 1, review, Besmer, 1983; 2, Besmer et al, 1986a; 3, 
Besmer et al, 1986b; 4, Naharro et al, 1984; 5, Neil 
et al, 1984; Levy et al, 1984; Mullins et al, 1984; 6, 
R. Fulton, D. Forrest, R. MacFarlane, D. Onions and 
J. Neil, Nature, in press.
Mechanism of c-myc 
Alteration
Species Associated Tumours Refs.
Transduction chicken Leukaemia, Lymphoma 1
Carcinoma
cat T cell lymphoma 2
Retroviral chicken B cell lymphoma 3,4
insertion mouse T cell lymphoma 5,6,
cat 7
rat 8
Other mouse Plasmacytoma (LAP gene) 9
insertion dog Transmissible venereal 10
tumour (Transposon)
Chromosomal man B cell lymphomas 11,12
translocation T cell " 13,14
Renal cell carcinoma 15
mouse Plasmacytoma 12
rat Immunocytoma 16
Amplif ication man Lung carcinoma 17
Colon " 18
Gastric " 19
Myeloid leukaemia 20
Glioblastoma 21
cat Spleen lymphoma 2
T cell " 2
Point mutations in:
coding regions man B cell lymphoma 22,23,24
chicken 25
non-coding regions man B cell lymphoma 26,27
mouse Plasmacytoma 28
REFERENCES: 1, Hayman, 1983; 2, Neil et al, 1984; 3, Hayward 
et al, 1981; 4, Noorii-Daloii et al, 1981; 5, Corcoran et al, 
1984; 6, Selten et al,1984; 7, D. Forrest et al, submitted; 8,
Steffen, 1984; 9, Greenberg et al, 1985; 10, Katzir et al,
1985; 11, Leder et al, 1983; 12, Marshall, 1985; 13, Erikson 
et al, 1986; 14, Shima et al, 1986; 15, Drabkin et al, 1985; 
16, Suraegi et al, 1983; 17, Little et al, 1983; 18, Alitalo et 
al, 1983; 19, Shibuya et al, 1983; 20, Collins & Groudine, 
1982; 21, Trent et al, 1986; 22, Rabbitts et al, 1984; 23,
Showe et al, 1985; 24, Gare et al, 1986; 25, Westaway et al,
1984; 26, Battey et al, 1983; 27, Wiman et al, 1984; 28, 
Stanton et al, 1984. (Referencing has been selective).
Table 1.2. Mechanisms of tumour-specific alteration of the 
c-myc gene in different species.
CHAPTER TWO 
MATERIALS AND METHODS
Part A. MATERIALS
2.1 Molecular clones
Recombinant plasmids and bacteriophage clones used in this study 
are listed in Table 2.1. These clones were stored in TE buffer (lOmM 
Tris.HCl pH 8.0, O.lmM EDTA) at -20°C. Clones were propagated in the 
following E. coll host strains: pBR322-based clones in strain HBlOl; 
pUC8-based clones in strain JM83; bacteriophage X clones in strain 
LE392 and M13 phage clones in E. coli strain JM103.
2.2 Chemicals, enzymes and other materials
Most chemicals and enzymes and other materials were obtained from 
The Sigma Chemical Company, BDH Chemicals, The Boehringer Corporation, 
BRL Inc., Difco Laboratories, Gibco and Pharmacia with the following 
exceptions: bacterial alkaline phosphatase from Worthington [further
purified according to Hall (1981)]; collodion dialysis bags from 
Sartorius; GeneScreen membranes from NEN; X-omat x-ray film from Kodak.
2.3 Media and Antibiotics
L-broth : 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) 
sodium chloride. Ampicillin was included when required at lOOpg/ml. 
L-agar : L-broth containing 1.5% (w/v) agar.
Top agar/x-gal: L-agar containing lOOpg/ml ampicillin and 
250pg/ml x-gal.
YT medium and agar and top agar for M13 cloning were prepared as 
described in the Amersham M13 cloning and sequencing handbook.
2.4 Radiolabelled nucleotides (obtained from Amersham)
Type
[0.-32p]dATP
[a-32p]dcTP
[a-32p]dGTP
[a-^2pjdTTP
[%-32p]ATP
[35s]dATPaS
Specific activity (Ci/mmol) 
3000
6000
600
Code
PB10204
PB10205
PB10206
PB10205
PB10218
SJ304
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2.5 Biological samples
All tumour and normal tissues and cultured cells were obtained from 
the Glasgow University Veterinary School. I occa sionally grew tumour 
cell lines obtained from the same source (section 2.2.12). Tumours 
analysed in this study are listed in Table 2.2. Several RNA and genomic 
DNA samples had already been prepared by R. McFarlane and G. Lees.
Part B. GENERAL METHODS
2.6 Restriction enzyme digestion of DNA.
Digests were performed in sterile 1.5ml Eppendorf microcentrifuge 
tubes according to the enzyme supplier’s specifications in the 
recommended buffers.
2.7 Ethanol precipitation of nucleic acids.
Generally, aqueous DNA and RNA samples were precipitated with 1/10 
volume of 3M sodium acetate and 2.5 volumes of ethanol at -70°C for 
0.5h, or -20°C for >2h. Samples were centrifuged at 9950g for 10 
minutes. The pellet was washed at least once with 80% ethanol. Genomic 
DNA samples were precipitated with 0.5 volume of 7.5M ammonium acetate 
and 2 volumes of this total aqueous volume of ethanol at -20°C for >2h.
2.8 Phenol extraction.
Residual agarose was removed from gel-purified DNA fragments by at 
least four phenol extractions using standard methods [Maniatis et al 
(1982)] and protein was removed from DNA samples with two or three 
extractions. When required, the resulting aqueous solution was reduced 
in volume by isobutanol extraction for ease of precipitation.
2.9 Gel electrophoresis.
In general, agarose gels were used for separation of nucleic acids 
>lkb in size and polyacrylamide gels for DNA fragments <lkb in size.
(A) AGAROSE GEL ELECTROPHORESIS 
Electrophoresis buffers (IX):
(i) TEA buffer: 40mM Tris.HCl pH8.15, 20mM sodium acetate,
20mM sodium chloride, 2mM EDTA.
(ii) TBE buffer: lOOmM Tris borate, 83mM boric acid, ImM EDTA pHB.O.
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(iii) MOPS buffer: 20mM MOPS pH7.0, 5mM potassium acetate, ImM EDTA. 
Sample loading solutions:
(i) lOX Sample loading solution for all gels (except where stated):
0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol,
25% (w/v) Ficoll-400 in distilled water.
(ii) Northern blot analysis RNA loading buffer: 50% (v/v) formamide, 
2.2M formaldehyde, IX MOPS buffer.
(iii) Formamide/dye loading solution for denaturing acrylamide gels: 
99% formamide/1% xylene cyanol.
Notes :
(i) During electrophoresis of gels with TEA buffer, the buffer was 
circulated using a peristaltic pump.
(ii) When required, after electrophoresis, gels were stained in 
ethidium bromide (lOpg/ml) for 0.5h then nucleic acids visualised 
using U.V illumination, and photography with a polaroid camera.
(iii) All acrylamide gel mixtures were filtered through Whatman
no.l filter paper using a Buchner flask prior to polymerisation. 
Minigels. 1% (w/v) agarose gels (13 x 9.5 x 0.5 cm) with TEA buffer
were used to analyse restriction enzyme digests of DNA. 1% (w/v)
agarose gels with TBE buffer were used to check recovery of M13 phage 
template DNA and to check that total cellular RNA preparations were not 
degraded. Samples containing 1/10 volume of lOX loading solution were 
applied ( l-2pg of DNA or ~4pg of RNA per lane) and electrophoresed at 
40V for 2-4h when using TEA buffer, or lOOV for 2h with TBE buffer.
Agarose gels for Southern blot analysis. Restriction enzyme digests 
of genomic DNA (20pg per lane) were electrophoresed in 0.5% (w/v)
agarose gels (19.5 x 14.5 x 0.5 cm) with TEA buffer at 25V overnight.
Preparative agarose gels. Required DNA fragments were isolated from 
DNA restriction digests by electrophoresis through typically, 1.2% 
(w/v) low melting point agarose gels (19.5 x 14.5 x 0.5 cm) with TEA 
buffer at 30-35V overnight at 4°C.
Agarose gels containing formaldehyde for Northern blot analysis.1% 
(w/v) agarose gels (19.5 x 14.5 x 0.5 cm) were prepared by dissolving 
2g of agar in 147ml of water in a microwave oven. When cooled to 60°C, 
33ml of formaldehyde and 20ml of lOX MOPS buffer were added, and the 
gel poured. RNA samples were freeze-dried, redissolved in 20jj.l of RNA 
loading buffer, loaded and electrophoresed at 120V for 2-4h using IX
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MOPS buffer.
(B) POLYACRYLAMIDE GEL ELECTROPHORESIS (PAGE)
Generally, 4% polyacrylamide gels (16.0 x 16.0 cm x 1.5 mm) were 
made as a 50ml stock solution containing 4% (w/v) acrylamide, 0.2%
(w/v) bisacrylamide, IX TBE, 1% (w/v) ammonium persulphate (APS) and
30[il of TEMED (Maniatis et al, 1982). 20pl samples (l-2pg of DNA) were
loaded per lane and electrophoresed using IX TBE buffer at 200V for
2-3h.
Denaturing PAGE. Polyacrylamide gels (40 x 20 cm x 0.3 mm)
containing 7M urea were used to fractionate products of DNA sequencing 
reactions and of RNA SI nuclease analyses. Except where stated, 6% 
acrylamide gels were used, which were made as a 60ml stock solution 
containing 6% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, IX TBE, 0.8% 
(w/v) APS, 25.2g of urea and 24pl of TEMED. Samples were redissolved in 
formamide/dye solution. Gels were electrophoresed at 1200-1500V for 15 
minutes prior to loading samples, and samples were electrophoresed at 
the same voltage for the appropriate time (e.g 1.5-4h) using IX TBE 
buffer.
2.10 Isolation of DNA fragments from preparative agarose gels.
The band of interest was located on the gel, excised with a scalpel, 
placed in a 50ml polypropylene tube (Falcon) with 5ml of distilled 
water and melted in a 70°C water bath for 10 minutes. The DNA was then 
purified by at least four phenol extractions and ethanol precipitation.
2.11 Isolation of DNA fragments by preparative PAGE.
The band of interest was excised from the . gel with a scalpel, 
crushed, and the DNA eluted into a solution of 500mM ammonium acetate, 
lOmM magnesium acetate, 0.1 mM EDTA and 0.1% SDS by overnight 
incubation at 37°C (Maxam & Gilbert, 1980). The aqueous solution was 
collected through siliconised glass wool and the DNA purified by 
ethanol precipitation.
2.12 Hybridisation analysis of DNA and RNA.
Hybridisation analyses were performed essentially as described in 
the GeneScreen hybridisation instruction manual (NEN, Boston).
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Solutions :
50X Denhardt's solution: 1% (w/v) of each of Ficoll-400, 
polyvinylpyrrolidone and BSA (Pentax fraction V).
2OX SSC: 3M sodium chloride and 0.3M sodium citrate.
2OX phosphate buffer: 0.5M Na2HP04/ 0.5M NaH2PÛ4 pH6.5.
Southern blot transfer of DNA. DNA samples were electrophoresed and 
transferred by the Southern (1975) method onto GeneScreen membranes. 
This involved dénaturation of the DNA in the gel in 1.5M NaCl/0.5M 
NaOH, followed by neutralisation in 3M NaCl/0.5M Tris.HCl pH7.0, then 
washing for Ih with IX phosphate buffer. Transfer was performed 
overnight (> 14h) in IX phosphate buffer. The membrane was then rinsed 
in IX phosphate buffer and baked at 80°C for 2-4h to fix the DNA.
Northern blot transfer of RNA. This procedure was the same as for 
DNA transfer except that the dénaturation and neutralisation steps were 
unnecessary, and transfer was continued for the longer time of >18h as 
this improves transfer of larger RNA molecules (Maniatis et al, 1982).
Hybridisation procedure. Standard high stringency conditions for 
analysis of feline nucleic acids with probes of feline origin (when 
using a probe derived from a different species, stringency was reduced 
as necessary): membranes were pre-wetted in 1% Triton-XlOO, then
prehybridised in sealed polythene bags in a 10ml volume containing: 50% 
(v/v) formamide (de-ionised), 5X SSC, 5X Denhardts solution, IX 
phosphate buffer, 10% (w/v) dextran sulphate, 0.1% (w/v) SDS and
lOOpg/ml of denatured salmon sperm DNA, at 42°C overnight with 
agitation. Then radioactive probe was added to a concentration of 
5ng/ml with a further 2ml of prehybridistion solution and hybridised 
overnight at 42°C with agitation. The next day membranes were rinsed in 
2X SSC several times at room temperature, then washed at 60°C with 
agitation in O.IX SSC/0.5% SDS, for Ih, including three changes of wash 
solution. Membranes were rinsed in O.IX SSC at room temperature for 
several minutes, dried on Whatman 3MM paper and sealed in thin 
polythene bags for autoradiography.
2 -13 Preparation of radioactively-labelled DNA fragments
Nick translation. DNA inserts for use as hybridisation probes were 
gel-purified from their vectors and radioactively-labelled using a kit 
provided by Amersham (code N.5000), which contained necessary enzymes
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(DNAseI and DNA polymerasel) and buffers. Generally, 0.5pg of DNA was 
made to 45pl with lOpl of buffer (containing non-radioactive dATP, 
dGTP, dTTP), lOOpCi of radiolabelled dCTP and distilled water. Then 5pl 
of enzyme solution was added, mixed gently and the mixture incubated at 
14°C for 2.5h. Unincorporated nucleotides were removed by 
gel-filtration through a Sephadex G50 column, eluted with 5mM Tris.HCl 
pH8.0/lmM EDTA/0.1% ( w / v )  SDS. Progress of the labelled DNA peak was 
monitored and peak fractions were collected. The specific activity of 
the labelled DNA was calculated (usually 1-2 x 10® cpm/pg) and the 
appropriate amount of labelled DNA was used immediately as 
hybridisation probe.
5' end-labelling. This procedure was used to radiolabel DNA 
fragments for use as molecular size markers, for use as SI nuclease 
mapping probes (Chapter 5) or for use as substrates for the chemical 
cleavage sequencing method. The DNA fragment (l-5pg) with overhanging 
5' ends or blunt ends was first dissolved in 90pl of TE pH8.0 and mixed 
with lOpl of bacterial alkaline phosphatase. The reaction was incubated 
at 37°C for 1.5h, then extracted with phenol and purified by ethanol 
precipitation. The DNA pellet was dissolved in 5pl of water, 2.4pl of 
lOX kinase buffer (O.IM magnesium chloride, 0.5M Tris.HCl pH8.0), 1.2pl 
of lOOmM DTT and 0.5pl of lOmM spermidine. Then 12pl (120pCi) of [% 
-®^P]ATP was added with 5 units of polynucleotide kinase to a total 
volume of 24pl. This was incubated at 31°C for 0.5h. The reaction was 
phenol extracted and unincorporated nucleotides removed by dialysis in 
a micro-collodion bag against TE pH8.0, or by gel-filtration through a 
Sephadex G50 column.
3'end-labelling. This procedure was used to radiolabel 
Hindlll-digested \DNA size markers and to make SI nuclease mapping 
probes (Chapter.6) by template-dependent extension of recessed 3* ends 
using DNA polymerase I Klenow fragment. 1-2 fig of DNA was mixed with 
5fil of buffer solution from a nick translation kit, lOfil of 
[a-®2p]dcTP, O.Sfil of lOOmM spermidine and 10 units of enzyme in a 
volume of SOfil. The reaction was incubated at room temperature for 5 
minutes, then 1 fil of chase solution (non-radioactive lOOmM dCTP) was 
added and incubation continued for a further 25 minutes. The reaction 
was phenol extracted and unincorporated nucleotides removed as 
described above. End-labelled probes could be stored at -20°C.
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2.14 Plasmid cloning
All recombinant plasmids made in this study were constructed in pUC8 
using ampicillin and colour selection for recombinant clones.
Solutions: lOX ligase buffer: 0.5M Tris.HCl pH7.6, 0.08M MgCl2• 
lOX DNA transformation buffer: lOmM of each of MgCl2, 
CaCl2 and Tris.HCl pH7.5.
Ligation. Vector and insert DNAs digested with appropriate enzymes 
were phenol extracted and ethanol precipitated. In general, insert DNA 
was added in lOX molar excess to 50ng of pUC8 in a lOpl volume 
containing IX ligase buffer, lOmM ATP, lOmM DTT and 6 units of T4 DNA 
ligase and incubated overnight at 14°C.
Transformation. Competent E. coli strain JM83 were prepared 
according to Hanahan (1983). Half of the ligation reaction was made to 
a lOOjil volume containing IX transformation buffer, mixed with lOOpl of 
competent cells and left on ice for 0.5h. The mixture was heat-shocked 
at 37°C for 5 minutes and transferred to 3ml of L-broth at 37°C for 
1.5h. Ampicillin (lOOpg/ml) was added and the mixture plated out at low 
and high densty on L-agar plates with a top agar/x-gal layer 
containing ampicillin (section 2.1.3). Plates were incubated overnight 
at 37°C. Several positive (white) colonies were picked, grown in small 
(10ml) cultures and plasmid DNA isolated (Maniatis et al, 1982) and 
digested with restriction enzymes to check that the plasmid represented 
the expected clone.
2.15 Nucleic acid preparations.
Guanidinium thiocyanate solution: 5M guanidinium thiocyanate, 50mM 
Tris.HCl pH7.G, 50mM EDTA, 5% (v/v) 13-mercaptoethanol.
Large scale preparation of plasmid DNA. Bulk preparation of plasmids 
followed the bacterial growth and alkaline lysis procedures given in 
Maniatis et al (1982) with final plasmid purification by centrifugation 
through CsCl/ethidium bromide gradients.
Feline genomic DNA. Liquid nitrogen frozen tissue was crushed then 
lysed in 5-lOml of guanidinium thiocyanate solution with 8-10 strokes 
of a loose fitting pestle in a Dounce homogeniser. Tissue culture cells 
were washed in phosphate buffered saline and lysed in guanidinium 
thiocyanate by pipette action. Sodium acetate was added to 20mM, then 
the DNA precipitated with an equal volume of isopropanol and spooled
27
onto a glass rod. The DNA was washed in 70% and 100% ethanol, dried, 
and redissolved in 5ml of lOmM of each of NaCl, EDTA, Tris.HCl pH8.0 
and 0.5% (w/v) SDS. Proteinase K (50pg/ml) was added and the mixture 
incubated overnight at 37°C, phenol extracted and dialysed against TE 
pH8.0. RNAse A (50fig/ml) was added and the solution incubated for 0.5h 
at 37°C, phenol extracted and dialysed as before. The DNA could then be 
stored at 4°C.
Feline total cellular RNA. Tissue samples or cells were lysed as for 
DNA preparation. Total cellular RNA was isolated by centrifugation at 
210,000g for 24h at 15°C through 5.7M CsCl as described in Chirgwin et 
al (1979). The RNA pellets were ethanol precipitated, redissolved in 
DEP-treated water and stored at -70°C.
2.16 DNA sequencing.
The M13 chain-termination method of Sanger et al (1980) and the 
method of chemical-cleavage of end-labelled fragments by Maxam and 
Gilbert (1980) were used in this study. Both methods were performed 
according to well-established protocols which were followed closely and 
will not be reiterated here. The protocol for M13 cloning and 
sequencing was described in the Amersham handbook, and made use of mplO 
and mpll vectors, and the chemical-cleavage method was described in 
Maxam and Gilbert (1980) with modifications in Stewart (1983) (Table 
2.3). In all cases the substrates for chemical-cleavage sequencing were 
single strands of DNA which were prepared as described in Chapter 5. 
The M13 method was preferentially used but occa sional short GC-rich 
sequences did not yield clear results with this method and the 
chemical-cleavage method was used to confirm these sequences.
2.17 Tissue.culture
Suspension cultures of leukaemic feline cell lines F422 and T3 (D, 
Onions et al, submitted) were grown in 50% Liebovitz L15/50% McCoys 5A 
medium supplemented with 2mM L-glutamine, 10% foetal bovine serum and 
400 units/ml of penicillin/streptomycin, to 5 x 10® - 2 x 10® cells/ml 
and were sub-cultured twice weekly.
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CLONE INSERT SPECIES
OF
ORIGIN
VECTOR REFS.
AND
NOTES
pCT4Pl v-myc cat pDCS 1
pCTBKO FeLV Ü3 
FeLV 05
cat PAT153 2
^SPF62 c-myc cat ÀJ1 3
^CM-l c-myc cat Xgt.WES 4
pFMC-1 c-myc cat pOC8 4
pSBl.8 c-myc cat pOC8 4
pS700 c-myc cat pOC8 4
pMC41HE c-myc man pBR322 5
pJ02 a-TCR man pBM322 6
pB400 J3-TCR man pOC8 6
Pim-1 pim-1 mouse pBR322 7
Table 2.1 Molecular clones used in this study.
Refs, and notes:
1, Neil et al (1984); 2, provided by J. Neil; 3, Mullins 
et al (1984); 4, clones generated in this study;
5, Dalla-Favera et al (1982); 6, Collins et al (1985);
7, Cuypers et al (1984).
All plasmid clones were grown using ampicillin selection.
Tumour case Lymphosarcoma FeLV +/ 
type
myc
alteration
84793 Thymic + V
84929 Thymic + V
F422* Thymic + V
T3 Thymic + V
Til Multicentric + V
T17 Thymic note 1 V
T5 Thymic + R, A
T7 Thymic +- R
T8 Thymic + R
T24 Thymic + R
T9 Splenic - A
TIO Thymic + -
T14 Thymic + -
T18 Thymic -
T19 Thymic + -
T21 Thymic - -
T23 Thymic - -
84904 Thymic + -
86503 Thymic - —
86800 Thymic + -
87416 Alimentary + -
89407 Thymic + -
89960 Thymic - -
FL74* note 2 +
Table 2 .2. Tumours analysed in this study.
Denotes tumour cell line; all other cases were 
primary tumours. All tumours were field cases except 
T5, T8, TIO and T24 which were experimentally induced 
(Chapter 4).
FeLV status was determined by virus isolation assay 
(Jarrett et al, 1982) and by hybridisation analysis of 
integrated proviruses using a U3 probe specific for 
exogenous FeLV (Casey et al, 1981).
Notes :
1. Serologically, T17 was FeLV (-), but tumour DNA was 
shown to contain FeLV proviruses (R. Fulton et al, in 
press).
2. The leukaemic FL74 line was established from a 
tumour in a kidney which had the
erythrocyte-rossetting property characteristic of 
lymphoid cells (Theilen et al, 1969;
D. Onions, pers. comm.).
Key to myc alterations: V, FeLV/myc provirus; R, 
rearranged c-myc gene; A, amplification of the c-myc 
locus.
G G + A C + T . c
•I.
Iql carrier ENA 
Iql ^ ^ D N A  
98ql CMS buffer
Iql carrier DNA 
Iql ^ ^ D N A  
Iliil H^O
Ivjl carrier DNA 
Iql ^^P-CNA 
6gl H^O
Iql carrier DNA 
Iql ^^P-DNA 
8gl sat. NaCl.
2 . O.Sql DMS 2.5ql pyr. form. ISql Hz. ISgl Hz.
3. 20°C, 4mins. 30°C, 70nins. 20°C, Smins. 20°C, 8mins.
4.
24ql DMS step 
400i%l Ar. ETOT freeze -70°C 
lyofhilise. 
add lOgl H^O 
freeze -70 C 
lyophilise.
SOgl Hz. stop 
250gl Ar. ETOH
5.
-70°C, I5ndns.
c'fuge (9950g) 
Smins.
-70°C, ISmins. 
c'fuge (9950g) Smins.
6 . SOgl 0.3M Na.Ac. 
2OO4I Ar. EIOH
60ipL 0.3M Na.Ac. 
200ql Ar. ETOH
7. repeat step 5 repeat step 5
8 . 20Cql 70% ETOH 200ql 70% ETOH
9. repeat step 5 repeat step 5
10 200gl 70% ETOH 200gl 70% ETOH
II. repeat step 5 repeat step 5
12. dry pellet dry pellet
13. lOOgl IM Piperidine
14. 90°C, 30mlns.
15. c'fuge (9950g) 30secs.
16.
freeze -70°C, lyophilise, add 20gl H^O, freeze -70°C, lyophilise, 
add 2O4I H^O, freeze -70°C, lyophilise.
Table 2.3. Protocol used for DNA sequencing by the Maxam and 
Gilbert method, modified by Stewart (1983).
Abbreviations: DMS, dimethylsulphate; Hz, hydrazine; sat. 
NaCl, saturated NaCl; pyr. form., pyridine formate, pH2; Ar. 
EtOH; Analar ethanol; Na.Ac., sodium acetate.
All reactions were performed in 1.5ml siliconised Eppendorf 
tubes. DMS and Hz wastes were disposed of into 5M NaCl and 3M 
ferric chloride respectively and steps involving handling of 
these chemicals were performed in a fume hood. After final 
lyophilisation at step 16, the radioactivity of each sample 
was determined by Cerenkov counting.
CHAPTER THREE
THE FELINE c-myc GENE: STRUCTURE AND RELATIONSHIP TO FELINE v-myc
GENES.
3.1 INTRODUCTION
The discovery of transduced v-myc and rearranged c-myc genes in 
feline leukaemias prompted a detailed characterisation of the feline 
c-myc gene. This was necessary so that the altered myc genes could be 
compared to the normal c-myc structure with the aim of understanding 
what changes may lead to oncogenic activation of the gene.
When this study began in late 1983, reports on the structure of the 
human, mouse and chicken c-myc genes showed that a highly related 
coding domain (of two exons, later designated as exons 2 and 3) was 
present in each of these species, which was a typical feature of the 
cellular progenitor sequences of a transduced v-onc gene (Watt et al, 
1983a; Gazin et al, 1983; Bernard et al, 1983; Watson et al, 1983). The 
human and murine genes showed most similarity, and they also possessed 
a common upstream exon (exon 1) with some puzzling features. It formed 
part of the mRNA but apparently was non-coding. There were also two 
distinct promoter-like elements (PI and P2) at the 5' end of this exon 
(Watt et al, 1983b; Battey et al, 1983). The significance of this 
structure was unknown but it suggested that expression of the gene may 
be subject to complex controls (Salto et al, 1983).
Preliminary Southern blot hybridisation analysis indicated that the 
feline c-myc gene was related to the gene in other species at least in 
coding exons 2 and 3 (Neil et al, 1984; Mullins et al, 1984). However, 
detailed comparison required isolation and characterisation of a 
molecular clone of the gene, which should also reveal whether an exon 
1 domain was present. The clone would be important to allow sequence 
comparison with transduced feline v-myc genes to investigate what 
structural changes might play a role in oncogenic activation of the myc 
gene. The clone would also provide probes to map in detail c-myc 
rearrangements in tumours (Chapter 4) and to analyse c-myc transcripts 
in normal and tumour cells (Chapter 5).
3.2 MATERIALS AND METHODS
All procedures were as described in Chapter 2 except those dealing
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with isolation of a clone of the feline c-myc gene from a bacteriophage 
X library which were described in Maniatis et al (1982).
Media. LAM broth : L-broth containing lOmM magnesium sulphate and
0.2% (w/v) maltose.
LAM agar : LAM broth containing 1.5% (w/v) agar.
LAM agarose: LAM broth containing 0.6% (w/v) agarose.
Outline. Previous Southern blot analysis of feline genomic DNA 
indicated that the c-myc gene was present on a 10 kb EcoRI fragment 
(Neil et al, 1984). Hence, an available, unamplified /\gtWES library of
500,000 clones containing EcoRI-digested, 8-15kb size-selected genomic 
DNA from normal feline embryonic fibroblasts of the FEA strain (Jarrett 
et al, 1973) was screened by the plaque hybridisation procedure 
(Benton & Davis, 1977) using a probe derived from a feline v-myc clone 
(pCT4/Pl; Neil et al, 1984).
Procedures. Positive plaques were identified as described in 
Maniatis et al (1982). Hybridisation was performed as described in 
Chapter 2 except that no dextran sulphate was used and the membranes 
were contained in polythene boxes. Duplicate phage impressions were 
analysed in the first round of screening to confirm positive plaques. 
Positive plaques were picked, and the titre of plaque forming units 
determined using E .coli strain LE392. Recombinant phage were replated 
in LAM agarose top layer on LAM agar for the next round of plaque 
purification. This procedure was repeated until well-separated plaques 
could be picked.
DNA was prepared from a single positive bacteriophage clone by a 
liquid lysis method. 2 x 10® bacteria were infected with ~ 10® pfu of 
the bacteriophage suspension and were then transferred into LAM broth 
for overnight growth and lysis at 37°C with agitation. The lysate 
supernatant was collected and treated with DNAsel (lOpg/ml) overnight 
at room temperature. 1/3 volume of 1.5% (w/v) SDS, 0.3M Tris.HCl pH9.0, 
0.15M EDTA was added and the solution incubated at 70°C for 0.5h. Then 
1/6 volume of 8M potassium acetate was added and the solution placed on 
ice for 0.5h. The supernatant was collected and precipitated with 3/5 
volume of isopropanol at room temperature for 0.25h. The pellet was 
collected, dried, redissolved in water and treated with RNAse A 
(50pq/ml) at 37°C for 0.5h. The \ DNA was precipitated, dried and 
redissolved in TE pH8.0 and stored at 4°C.
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3.3 RESULTS AND DISCUSSION
3.3.1 Isolation of clones of the normal feline c-myc gene.
Three myc-hybridising plaques identified during first round 
screening were picked for plaque purification. Unfortunately, one 
plaque did not yield further positive plaques. The other two (XCM-1 and 
-2) yielded well-separated, positive plaques from which the
bacteriophage DNA was purified. The 10 kb inserts were isolated and
sub-cloned into pUC8 to generate plasmids pFMC-1 and -2. The 
restriction map of pFMC-1 was determined using single and double enzyme 
digests, and agreed with the tentative map determined by hybridisation 
analysis of genomic DNA (Fig.3.1),
3.3.2 Location of exons on the c-myc clone.
Exons 2 and 3 : Duplicate Southern blots of pFMC-1 digests were
analysed with human exon 2 and 3-specific probes (Table 3.1; Fig.3.2). 
The exon 2 probe hybridised to fragments from the region expected 
according to the preliminary map. Thus, a 500 bp PstI band, a 2.0 kb 
Bglll band and a 2.5 kb BamHI . band located the exon 6.5-8.0 kb
from the 5' end of the insert (Fig.3.1). The exon 3 probe hybridised 
to fragments from the predicted exon 3 region, notably a 1.3 kb BamHI 
band and a 2.0 kb PstI band derived from the extreme 3' end of the 
pFMC-1 insert. Subsequent sequence analysis showed the 3' EcoRI site of 
the cloned insert to be 3' to the exon 3 translational stop codon but 
5' to the putative polyadenylation signals (Stewart et al, 1986b). The 
locations for exons 2 and 3 agree with those of other workers who have 
isolated feline c-myc clones (Mullins et al, 1984; Soe & Roy-Burman, 
1984).
Several bands not from the expected region also hybridised to the 
exon 3 probe. However, these bands did not prevent assignment of the
exon 3 location shown, as some coincide with exon 2 region fragments.
This can be explained by a short exon 2 sequence at the 5' end of the 
v-myc-derived probe used. The remaining unexpected bands result from 
limited hybridisation to vector fragments (e.g. EcoRI digestion 
yielded a hybridising band for the expected 10 kb insert but also a 
fainter 2.7 kb linearised pUC8 band). The positions of exons 2 and 3 
have been confirmed by sequence analysis by colleagues in Glasgow 
(Stewart et al, 1986b).
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Exon 1 : The location of exon 1 was not known, since a human exon
1-specific probe failed to give a hybridisation signal with feline
genomic DNA even under conditions of reduced stringency. However, the 
probe detected bands in digests of the pFMC-1 clone using low
stringency hybridisation conditions (Table 3.1; Fig.3.3). The bands
detected, including a 2.3 kb Bglll band and a 1.8 kb Sall/BamHI band, 
located exon 1 4,7-6.5 kb from the 5' end of the pFMC-1 insert. To 
facilitate sequence analysis, the Sall/BamHI 1.8 kb fragment was 
sub-cloned into pUC8 to generate the plasmid pSBl.8. Hybridisation 
analysis of digests of pSBl.8 confirmed that it contained exon 1, 
approximately in the middle of the insert (Fig.3.3).
Soe and Roy-Burman (1984) had previously reported the location of 
the feline c-myc exon 1 to be further downstream than the that given 
here. Since their report was based only upon Southern blot analysis 
using a murine exon 1 probe, and since the location I report has been 
supported by DNA sequencing and RNA SI nuclease mapping (Chapter 5), 
the location Soe and Roy-Burman propose appears to be incorrect. This 
may be because the murine probe is less closely matched to feline c-myc 
exon 1 than is the human probe which I used (section 3.2.3).
3.3.3 Nucleotide sequence of the exon 1 region.
The sequencing strategy is shown in Fig.3.4. The sequence of the 
exon 1 region was of interest for several purposes :
(a) To confirm the location of exon 1.
(b) To compare its sequence to sequences of unknown origin at the 5' 
end of transduced FeLV v-myc genes.
(c) To investigate the function of this region of the gene. For 
example, could transcriptional control signals be identified?
(d) To facilitate analysis of c-myc transcripts in normal and tumour 
cells (Chapter 5).
3.3.4 Consensus sequences in the exon 1 region.
The sequence is presented in Fig.3.4. The putative 575 bp exon is 
enclosed within a box. The 5' limits were assigned to consensus RNA cap 
sites at positions 551 (PI) and 732 (P2) which were respectively 24 and 
27 bp downstream from TATA boxes (Fig.3.5B). The PI and P2 putative cap 
sites were homologous to those in the human and murine c-myc genes 
(Bernard et al, 1983; Watt et al, 1983b).
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The 3 limit was identified by alignment with a consensus splice 
donor sequence, and was homologous with the splice donor identified in 
human and murine c-myc cDNA clones (Fig.3.5A; Stanton et al, 1984). 
That this site was a splice donor was supported by comparison with the 
structure of FeLV v-myc genes, which appear to be effectively spliced 
cDNA versions of the c-myc gene (Fig.3.TA).
Several putative binding sites for the SPl transcription factor are 
also shown. Only sites which perfectly match the consensus sequence or 
its complement are shown (Dynan & Tjlan, 1985). Several sites are 
clustered around the PI and P2 region, in accord with their possible 
role in transcriptional initiation. It is noteworthy that the three 
sites immediately 5' to the PI promoter-like region are identical in 
location and orientation to sites identified in the human c-myc gene 
from sequence and DNA footprinting studies (B. Whitelaw, J. Lang and N. 
Wilkie, pers. comm.).
3.3.5 Comparison of the c-myc exon 1 region in different species.
The sequence of exon 1 of the feline c-myc gene is iù % and % 
related to that of the mouse and man respectively. Exon 1 of the 
chicken c-myc gene bears no significant homology to that of the 
mammalian gene and is closer to exon 2 than is exon 1 of the cat, man 
and mouse (Shih et al, 1984; Linial & Groudine, 1985; Nottenburg & 
Varmus, 1986). The closest homology is between the cat and man, 
consistent with exons 2 and 3 also being most closely related between 
these species (Stewart et al, 1986b). The closer relationship between 
the feline and human genes at the DNA level follows the same tendency 
as overall genetic linkage where the feline and human linkage maps are 
more similar than are those of man and the mouse (O'Brien, 1986).
The 5' flanking sequences of the feline, human and murine c-myc 
genes are also highly related. This remarkable cross-species homology 
in a presumably non-coding region supports the proposal that this 
region performs a common control function (Siebenlist et al, 1984). 
Studies on the murine and human c-myc genes have identified a negative 
control element 0.4- 1.0 kb upstream of exon 1 (Remmers et al, 1986; B. 
Whitelaw et al, pers. comm.). The 550 bp region upstream of the feline 
c-myc gene is 78% homologous with the human gene and 68% with the mouse 
gene. The 130 bp immediately upstream of PI including the three SPl 
sites mentioned above, is 84% related to the human sequence. Most
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mismatches are scattered nucleotide substitutions with only a few more 
extensive deletions or insertions. These sequence data suggest 
functional studies on the feline exon 1 region would reveal similar 
features as have been shown for the human and murine genes.
3.3.6 The coding potential of exon 1.
Exon 1 of the feline c-myc gene appears to be non-coding since it 
contains no translation initiation codons and stop codons are present 
in each reading frame, which agrees with reports on the human and 
murine c-myc genes (Fig.3.6; Bernard et al, 1983; Salto et al, 1983). 
Gazin et al (1983) reported the presence of a 188 codon open reading 
frame in the exon 1 region of the human gene. Although a homologous 
translation initiation codon is present at the PI TATA box of the 
feline gene (reading frame 2, Fig.3.6), the putative product would be 
terminated after only 59 codons, and is not related to that reported 
for the human gene, except for 10/12 N-terminal residues. Related 
coding sequences are present further downstream, but these cross
between the three reading frames. This divergence suggests that if 
exon 1 of the mammalian gene does code for a protein, it is not 
conserved between these species. This lack of conservation contrasts 
with the highly related reading frame of exons 2 and 3 of the human, 
mouse and feline genes (Bernard et al, 1983; Watt et al, 1983a; Stewart 
et al, 1986b).
Although it appears unlikely that feline c-myc exon 1 codes for a 
protein, this is not excluded if c-myc transcription could initiate 
further upstream than the presumptive PI start site such that a
translation initiation codon could be included in the mRNA (Fig.3.6). 
Bentley and Groudine (1986b) have recently reported the cloning of 
human c-myc cDNAs with multiple initiation sites originating from a 
promoter-like region (PO) 500 bp upstream of PI. Also, Gazin et **al 
(1986), have reported serological detection of a human cellular protein 
possibly related to the exon 1 product they had predicted earlier
(Gazin et al, 1983).
3.3.7 Structural comparison of feline c-myc and v-myc genes.
Determination of the structure of the feline c-myc gene allowed
comparison with FeLV v-myc genes to identify possible coding
alterations. Fig.3.7 shows the structure of three independently 
isolated myc-transducing FeLVs. The LC, CT4 and FTT isolates each
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contain the c-myc coding exons 2 and 3, which are invariably intact, 
with the qualified exception of FTT where a nonsense mutation 
terminates the v-myc reading frame two codons before the normal c-myc 
stop codon. Similarly, avian myc-transducing viruses (Reddy et al, 
1983; Hayflick et al, 1985; Walther et al, 1986) contain intact myc N 
and C termini. This supports the view that the entire myc coding 
sequence without N- or C-terminal truncation is required for 
transforming activity, as indicated by recent mutagenesis studies on 
the MC29 v-myc gene (Heaney et al, 1986).
The FeLV v-myc genes shown contain portions of exon 1 (Fig.3.5). In 
contrast, avian v-myc genes do not, but instead contain sequences which 
may derive from intron 1. Assuming that the process of transduction 
begins with proviral integration 5' to the region to be transduced 
(Swanstrom et al, 1983), then this contrast between feline and chicken 
v-myc genes may reflect differences in the initial insertion sites at 
the c-myc genes in these species. This is supported by finding that 
ALV proviruses are integrated predominantly in intron 1 in chicken 
bursal lymphomas (Shih et al, 1984; Robinson & Gagnon, 1986), whereas 
FeLV proviruses are most commonly found upstream of exon 1 in feline 
thymic lymphomas (Chapter 4).
3.3.8 Predicted products of feline y-myc genes.
The v-myc product of the CT4 and FTT proviruses may be encoded by a 
spliced, sub-genomic RNA and translated from the normal c-myc 
initiation codon without fusion to any virus-coded products, since the 
v-myc genes are 3' to the the FeLV env gene splice acceptor signal 
(Fig.3.7). In contrast, FeLV-LC may express a gag-myc fusion product 
since its v-myc gene is joined in-frame with the gag p30 coding region. 
This fusion product would include 9 novel amino acids: five coded by
exon 1 sequences and four by the short exon 2 leader.
Avian v-myc genes display similar modes of expression (Bister, 
1984). Like FeLV-CT4 and -FTT, the jXIPg and OKIO viruses may express 
their v-myc products from spliced sub-genomic RNAs. However, in 
contrast to FeLV, the location of the avian viral splice donor for 
producing sub-genomic env RNAs predicts that the myc products would be 
fused to the six N-terminal gag residues (Ficht et al, 1984). 
Similarly to FeLV-LC, expression of the v-myc genes of MC29 and CMII, 
and an alternative mode of expression of OKIO to that mentioned above.
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would generate myc gene products which are fused to substantial viral 
structural gene components.
3.3.9 Coding differences between c-myc and v-myc genes.
The coding differences between feline c-myc and v-myc genes are 
listed in Table 3.2. FeLV-LC v-myc has no coding changes relative to 
c-myc, and the only predicted difference to normal c-myc is fusion to 
the gag component. This is strikingly similar to the avian CMII gag-myc 
product which is unchanged compared to c-myc except for a single amino 
acid substitution at the C-terminus (Walther et al, 1986).
The FeLV-CT4 and -FTT v-myc genes show few coding changes relative 
to c-myc, and the amino acid substitutions present result from single 
nucleotide changes. FTT has one change at position 236 (Glu-Lys) and 
one which prematurely terminates the v-myc reading frame two codons 
from the end of the normal c-myc reading frame. CT4 has substitutions 
at positions 137 (Lys-Glu) and 214 (Ala-Thr) and a two residue
insertion at position 438-439 due to a six nucleotide duplication.
There is no consistently altered codon in the three feline or four 
avian v-myc genes indicating that no specific amino acid change is 
obligately required for activation of the myc gene. The evidence from 
the LC and CMII v-myc genes indicates that no coding changes may be 
necessary. This view is supported by the sequences of several
rearranged c-myc genes which are not altered compared to the normal
gene (Battey et al, 1983; Wiman et al, 1984; Stanton et al, 1984).
Although specific codons are not consistently altered, there may be 
more general domains in which mutations would enhance myc oncogenic
function. Such domains may be indicated as highly related regions of 
different members of the myc gene family. One particular domain,
corresponding to residues 47-65 of the feline c-myc gene^ , is identical
in the c-myc genes of the cat, chicken, mouse, fish and man, and in the 
N-myc genes of the mouse and man (Stewart et al, 1986b; van Beveren et 
al, 1985; Van Beneden et al, 1986; DePinho et al, 1986; Stanton et al, 
1986). Sequence data shows that this domain may be more frequently 
mutated than other regions in transduced and rearranged myc genes
(Papas & Lautenberger, 1985; Westaway et al, 1984; Rabbitts et al,
1984; Showe et al, 1985; Murphy et al, 1986).
It is possible that coding changes augment the transforming activity 
of transduced myc genes. The avian MC29 and MH2 viruses and constructed
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murine viruses carrying MC29 and MH2 v-myc genes, generally transform a 
wider spectrum of cell types than do the FeLV/myc viruses (GT3 and FTT) 
which have been studied so far {Hayman, 1983; Morse et al, 1986; D. 
Onions et al, in press). Perhaps the location and/or greater number of 
coding changes in avian v-myc genes partly determines a wider 
transforming spectrum. This may partly explain the altered transforming 
spectrum of the avian HBl virus, derived from a 
transformation-defective MC29 myc deletion mutant, which has recovered 
c-myc sequences (Enrietto et al, 1983; Smith et al, 1985). However, the 
role of coding changes in myc oncogenic function remains to be 
systematically studied for the v-myc or c-myc genes of any species.
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EXON 1 EXON 2 EXON 3
Clone
Species
Insert
pMC.41 c-myc 
human
Xhol/PvuII445
Hybridisation formamide: 30' 
conditions temp. °C : 39
Wash
conditions
temp. °C : 50 
2X SSC
pCT4P2 v-myc 
cat
PstI450
50%
42
60
O.IX SSC
pCT4Pl v-myc 
cat
Pstl/EcoRI400
50%
42
60
O.IX SSC
Table 3.1. Origin of probes and hybridisation conditions used 
to locate exons 1, 2 and 3 on the pFMC-1 feline 
c-myc clone.
Probes were purified inserts. Except where specified above, 
hybridisation conditions were as described in Chapter 2.
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Fig.3.1. Structure of the feline c-myc gene.
Exons 1 to 3, indicated as black boxes are oriented 
5' to 3' from left to right. The restriction enzyme 
map of the 10 kb EcoRI insert of the pFMC-1 clone 
is shown below.
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Fig.3.2. Location of c-myc exons 2 and 3 on clone pFMC-1.
An ethidium bromide stained gel of pFMC-1 digests is 
shown on the left. Duplicate Southern blots of this 
gel hybridised with exon 2 and 3-specific probes are 
shown in the centre and on the right respectively (Table 
3.1). Lanes: 1, Pstl/BamHI
2, BamHI
3, BamHI/Sall
4, Sail
5, Bglll
6, EcoRI _
M, Hindlll-digested ^DNA labelled with P.
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0 5 7 -
M 1 2 3 4 5 6  1 2 3 4 5 6
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Fig. 3.3. Location of exon 1 on clones (a) pFMC-1 (b) pSBl.8
Ethidium bromide stained gels of plasmid digests are 
shown to the left of corresponding Southern blots 
hybridised with an exon 1-specific probe (Table 3.1). 
Lanes; M, Hindlll-digested ADNA labelled with 
(a) pFMC-1 (b) pSBl.8
1, PstI 1, Bgll
2, Pstl/BamHI 2, Bgll/BamHI
3, BamHI 3, Bgll/Sall
4, BamHl/Sall 4, PvuII
5, Bglll 5, PvuII/BamHI
6, Bglll/Sall 6, Smal
7, Bglll/Xbal
8, Xbal/Sall
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1 GTCGACACT AACACCCCACACCCTC8GAGCGC8CGCCCAT AAAT ACCCCTTCTTCCCTT8 60 
61 TCTTC8CGGGATTT ATTTTCCAAACGCTGCCCTTTCCCCAQCCTTC8GGAGGCGCCC8TC 120 
121 CACCCGGGACGT8CATGGCGT8GC8GTGGGTACAC8GTGTGTTCC8T8TT8AA88CTCA8 180 
181 CTGTTCCGCCTGC8AT8ATTTAA8CAC8CAAGACAA8TAT8CGGTTT8TCCA8CC8C8C8 240 
241 CT8CC8C86AG8A8CAC8G8A8AAA8GCAGCG88TTTBAOC8G8A8CAAAA8AAAAT8GT 300 
301 AGGC6C8CGCA8TTAATTCAT8CTBC8CTCT8ACT8TTTACATCC8ATC8CTC8GC8CAC 360 
361 T86AGT8CCAQeCAGAAAG88CC8A8TCCTCCTCCCCAACCTCCCCCCCCCACCC^8CC 420 
421 ÇAGCCA6TCCTCCGCA8AA6C8CCCCTCCCCGGCTCCCAAAGCGGAGGGÇ8g86GA8A8A 480
4 8 1  8A A A A A A G A T C C T C TC TC G C C G A A TC C^CG CCCACCGGCCCTTTTAT/yrB C G A G 6G TC T6C  5 4 0  
5 4 1  GCGGTC8AGG<ACCCCCGAGCTBCBCTCTCCCCGCCBCAGCTGCCGCC6CCGBCTCGCGCC
6 0 1
6 6 1
7 2 1
7 8 1
8 4 1
9 0 1
9 6 1
1021
1 0 8 1
CCGGCTGCTGCCTGGCGCCCTGCCGGCTTCGGGAAGGGCAGGGCTATTCAGGGGCTTGGC
G GG AAAAAG AG AACAG AG G G G AG G G ATC G TG C CTAG C TCTG ffÂT^AAAG CC G G TTC TTG G
. P2______._________^ _________ ._________ . ________
ggctttatctgIâctctctgtagtaatcctagcaagaggcagagggagcgacgggcgcgcc
CGCCTGGGTAGAAGAGCAGAGCGAGGCGAGCGAGCCGAGTCCGGCTCCGGGCGCCCGGGG
AAGGGAGATCCGGAGTGAAAGGGTGCTTCGCCTCCGGCCCACCCCACCCTGCCCGgCGCC
ÇC CT6CCAGCGG TG CG CAACTCCCCG CCGCACCCG CG AAACTTTG CCGG TTG CG GCGGGC
GgAC ACTG TTC CC TG G AACTTACAAC ACC CG AG CAAG AAC G C G ACTC TCC G G TC CG CCTA
TTTG G G G AAACACTTCTCCCCTACG CTG CCCG GG ACCCG CTCCTCTG AAAG GG CG CTCCT
600
660
7 2 0
7 8 0
8 4 0
9 0 0
9 6 0
1020
1 0 8 0
C G C C G C TTTTCG G ACG CTG G ATTTC CTTCG G ATAG TG G AAAAC CC e GTAAGCGCCCGGAT 1 1 4 0
1 1 4 1  C TATTTG TC TTC TC A TTTA TTTG C C C C A C C G C TTG AATG C C G C G AC G AG TC G AA G TC G AA 1 2 0 0  
1 2 0 1  TG C C C C AATC G G G G G TC TTTTC TG C C A TTC C TG C G C TA TTG A C A C TTTTTC TC A G AG TA G  1 2 6 0  
1 2 6 1  TTG TG GTAGCTCCGG G GTGGGGTGAGGACGACCCAGAACTGATGGGGTAGAGTGGCTTGT 1 3 2 0  
1 3 2 1  CAG G ATG G G A G G G C AAA C C G G TG C G TTTTTG AA AC TC G TC TTTAG AG ATTTTG C TC ATG T 1 3 8 0  
1 3 8 1  A T A C T G A G C G TC C C TG G A C C G G TT G G A C A TTC C TT C G TTTA TTC G A TT A A T TC G TTTT G A  1 4 4 0  
1 4 4 1  TTTTTTGGAGCGGGGAGGGGGGGGGTGGGGAGGGAGTGCCGGCTTCGCGGTGGGCAGAGA 1 5 0 0  
1 5 0 1  G CCCTCCCTGTACATCC CG AG CTC CTG G G AG TAAG AATTACAAATTG C TG TG G G AG C CG G  1 5 6 0  
1 5 6 1  AG AG CG TCC G C CG CC G C TG ACTTTTAG C G C TG G CTC AAAG G G ACTTTAAATTTCG G C TTA 1 6 2 0  
1 6 2 1  G CCACTTTGCTAG ACGGCCTGTTGCTTCGCTGCGGCCTCGÇCGCCCGGCATCCCCGGG 1 6 7 8
Fig.3.4. Strategy and results of nucleotide sequence analysis 
of the exon 1 region of the feline c-myc gene.
Top: Strategy. A restriction map of the insert of plasmid 
pSBl.8 is shown with exon 1 in the centre. PI and P2 
indicate promoter-like elements. Arrows below the map show 
the direction in which fragments were sequenced. o> indicates 
M13 clones, and ♦> fragments sequenced by chemical cleavage.
Bottom: Sequence. The exon boxed from positions 551-1126. 
Consensus sequences : PI and P2 TATA boxes are marked 
(positions 535 and 712). Putative SPl binding sites (GGGCGG 
or CCGCCC) are marked by small arrows under the sequence.
A  EX0N1
CONSENSUS SPLICE DONOR, C/AA(^TA/8AGT
FELINE c-oy£, CTBGATTTCCTTCQQATASTSGAAAACCCI^BTAASCSCCCOQATC
HUMAN c-fiyt cDNAi CTSGATTTTTTTCGGGTAGTGGAAAACCAcjcAGCCTCCCSCGACGATS
F*LV-LC v-gu£c_, 8GATAGTSGAAAACCCcjcAGSCTSCCGCGATS
FeLV-FTT v-gy&, CTGGATTTCCTTCGGATAGTQGAAAACCO^ GCT8CCGCGAT6
F"(-V-CT4 v-@^: . . (CTCCSGAGTSA) .... 263bp CC^CAGGCTSCCGCOATS
B +1 R N A
CONSENSUS RNA CAP SITE: G-GTATAA/TAA/T-G G..9-17bp..Y v|aYYYYYG
FELINE c-myc PI: CTTTATAT GC GAGGG. . . lObp. . .CGAGG^ÆCCCCGAGCTGCGC
P2: CTGTATAA AA GCCGG...13bp...ATCT^ACTCTC
Fig.3.5. Alignment of sequences at the 5' and 3' ends of exon 
1 with consensus promoter and splice donor signals.
(A) Splice donor. The sequence of the feline c-myc genomic 
clone is aligned with a consensus splice donor signal (Mount, 
1982) and with the exon 1/exon 2 junction of a human c-myc 
cDNA clone (Watt et al, 1983a) and with the exon 1/exon 2 
boundaries of clones of three FeLV v-myc genes (Braun et al, 
1985; Stewart et al, 1986; D. Doggett et al, submitted). Exon 
1 sequences present in these v-myc genes are shown in 
entirety.
(B) Promoters. The sequences of the feline c-myc PI and P2 
regions are aligned with a consensus TATA box and RNA cap 
site sequences (Breathnach & Chambon, 1981). (-) = any 
nucleotide; Y = pyrimidine.
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Fig.3.6. The coding potential of the exon 1 region of the 
feline c-myc gene.
The arrows marked PI and P2 indicate the location of the 
exon within the sequenced region. Below this line the 
location of all potential translation initiation (ATG) and 
stop codons are shown as small vertical lines in each reading 
frame.
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Fig.3.7, Structures of three FeLV/myc proviruses.
A non-recombinant FeLV provirus retaining gag, pel and env 
genes is shown for comparison. U3, R and U5 regions are 
marked in the 5' and 3' LTRs. SD and SA identify putative 
viral splice donor and acceptor sites for sub-genomic env 
transcripts. The v-myc structures were based on sequence 
data: LC, Braun et al, 1985; CT4, Stewart et al, 1986;
FTT, D. Doggett et al, submitted.
Regions corresponding to c-myc exons 1, 2 and 3 are shown 
above the LC provirus; UT = c-myc exon 3 untranslated 
sequence. Predicted v-myc products are shown below each 
provirus as black boxes. The gag part of the LC gag-myc 
product is shown as an open box. A 350 bp deletion in pol is 
marked in the FTT provirus.
The CT4 clone 3 ’ end was at the EcoRI site 3* to the c-myc 
translation stop codon; hence, the v-myc 3' terminus is 
marked as a dashed line to indicate this uncertainty. The 
presence of the CT4 3' LTR was shown by Southern blot 
analysis of the tumour DNA from which CT4 was isolated-
Normal c-myc gene FeLV v-myc genes
CT4 LC FTT
Codon Amino acid
157 AAA Lys GAA/Glu. — —
214 GCC Ala ACC/Thr
235 GAG Gill - - AAG/Lys
285-286 - TCTGCC/Ser-Ala
insertion
359 CAC His - - GAC/Asp
438-439 Cys-Ala - - premature
TGTGCA termination
(TGAGCA)
Table 3.2. Coding differences between feline c-myc 
and v-myc genes.
Table compiled from sequence data in Braun et al, 1985; 
Stewart et al, 1986b; D. Doggett et al, submitted. (-) denotes 
no change in v-myc relative to c-myc sequence. In FTT v-myc, 
codon 438/TGT is changed to TGA/stop which terminates the 
reading frame two codons before the normal c-myc stop codon.
CHAPTER FOUR
REARRANGEMENTS OF THE c-myc GENE IN FELINE TUMOURS
4.1 INTRODUCTION
Rearrangements of the c-myc gene were first detected in ALV-induced 
chicken bursal lymphomas, where proviruses were inserted at the c-myc 
locus (Hayward et al, 1981). Then studies on human Burkitt's lymphomas 
showed that chromosomal translocations caused abnormal joining of 
immunoglobulin loci to the c-myc gene (Leder et al, 1983). This 
provided indirect evidence that the myc gene may be involved in 
oncogenesis by means other than transduction by avian retroviruses.
Since then, the c-myc gene has been found to be rearranged in a
variety of tumours. Frequently one mode of rearrangement of the c-myc
locus has been found to be characteristic in a given type of chicken, 
mouse or human tumour. Proviral insertions are commonly found in avian 
and murine retrovirus-induced bursal and thymic lymphomas respectively 
(Hayward et al, 1981; Robinson & Gagnon, 1985.;, Corcoran et al, 1984; 
Selten et al, 1984; O'Donnell et al, 1985), chromosomal translocations 
characterise some human and murine B-cell lymphomas (Leder et al, 1983; 
Marshall, 1985), and amplification has been found in various human 
carcinomas and a myeloid cell line (Alitalo et al, 1983 ; Collins &
Groudine, 1982; Little et al, 1983).
FeLV-associated feline thymic lymphosarcomas provide another useful 
perspective concerning myc oncogenic potential since in these tumours, 
transduction of myc by FeLV and rearrangement of the c-myc locus have 
been observed (Neil et al, 1984; Levy et al, 1984; Mullins et al, 
1984). Although study of myc transduction by FeLV has been facilitated 
by sequence analysis of three distinct v-myc genes and of the normal 
c-myc gene (Chapter 3) little information has been available regarding 
the nature of the feline c-myc gene rearrangements.
Preliminary Southern blot hybridisation data indicated that the 
c-myc gene was rearranged in several feline lymphoid tumours (Table
4.1). These include field cases and experimental tumours. All tumours 
were FeLV-positive thymic lymphosarcomas, except for case T9 which was 
an FeLV-negative spleen tumour. This chapter concerns characterisation 
of the rearrangements in more detail by hybridisation analysis of 
genomic DNAs.
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4.2 RESULTS
To characterise the c-myc rearrangements, hybridisation analyses 
with c-myc-derived probes (shown in Fig.4.1) were performed on 
comparative restriction enzyme digests of tumour and control tissue DNA 
from the same animal. Restriction enzyme sites were located within the 
rearranged DNA relative to a reference site distal to the region of 
origin of the probe i 63. iD.
4.2.1 Proviral insertions in tumours T7, T8 and T24.
Preliminary analysis of tumour T24 DNA using probe 4 identified 
abnormal, tumour-specific Hindlll and EcoRI bands which were <2 kb 
larger than the normal bands (Fig.4.2). This indicated the presence of 
a small insertion of <2 kb within the normal 10 kb EcoRI fragment since
the EcoRI and Hindlll fragments were increased in size to the same
extent. This also showed that the insertion was between the EcoRI site
5' to exon 1 and the 3' most of two PstI sites in exon 2. The equal
intensities of the normal and rearranged bands in tumour DNA suggested 
that the tumour consisted of a clonal population of cells carrying one 
mutant and one normal c-myc allele.
Further analysis using probe 1 on Sall/BamHI digested DNA detected 
an extra 3.0 kb fragment ~1.3 kb larger than the normal band, locating 
the insert within the Sail and BamHI sites which normally encompass
exon 1 (Fig.4.3). That the insertion was upstream of the BamHI site in
intron 1 was supported by digestion with Sall/Bglll and Sall/Hindlll
which indicated that the Bglll and Hindlll sites had been displaced 
downstream by the same extent ( 1.3 kb). Sall/PstI digestion revealed a 
normal 3.1 kb band and a 1.9 kb band suggesting that the insert
introduced a new PstI site 1.9 kb 3' to the Sail site.
Probe 1 also detected an unexpected 4.5 kb band in some control DNA 
lanes (Sall/Bglll, Sall/PstI) which is probably due to a contaminating 
plasmid, since its size does not agree with the normal c-myc map, and 
it is only present in some control and not tumour DNA lanes. For these 
reasons I have disregarded this band in discussing the results above.
Hybridisation of probe 2 to Pstl/BamHI and Pstl/Bglll digested DNAs 
revealed no tumour-specific bands, confirming that the insert was 5* to 
the intron 1 BamHI site (Fig.4.3). Digestion with PstI and Pstl/Kpnl 
localised tumour-specific PstI and Kpnl sites 2.4 and 2.1 kb
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respectively upstream of the PstI site at the 5' end of exon 2. This 
suggested that the insert consisted of a truncated FeLV provirus 
retaining a 5' LTR orientated in the same transcriptional direction as 
c-myc, since PstI and Kpnl sites are characteristic of the LTRs of 
exogenous FeLV proviruses (Mullins et al, 1980; Neil et al, 1984).
Using a similar approach the T7 and T8 rearrangements were shown to 
consist of approximately full-length FeLV proviruses retaining two 
LTRs, integrated 0.5 and 2.5 kb respectively upstream of c-myc exon 1, 
but in the opposite transcriptional direction to the gene (Fig.4.5). In 
tumour T8 it had previously been shown that FeLV U3 sequences were
linked to the altered c-myc fragments (Neil et al, 1984). Again, these 
tumours retained a single normal allele at approximately the same 
intensity as the mutant allele (D. Forrest et al, submitted).
4.2.2 Rearrangement and amplification 3* to c-myc in tumour T5.
Tumour T5 presented a complex rearrangement at the 3 ’ end of the
c-myc gene. Analysis with probe 3 showed that the tumour-specific
restriction enzyme sites -were not typical of an FeLV provirus
(Fig.4.4). Neither did analysis using a U3 probe specific for exogenous 
FeLV proviruses indicate linkage of the rearranged fragments and FeLV 
sequences (J. Neil, pers. comm.). Probe 3 detected no rearrangement 
upstream of the PstI site 0.5 kb 3' to the most 3' of the two exon 3 
polyadenylation signals. The intensity of the signal was 1.5 times 
that of the equivalent band in control DNA. On Hindlll digested DNA, 
two tumour-specific bands of 4.3 and 4.0 kb and a normal band of 3.5 
kb were detected, each of which was of approximately equal intensity. 
Upon Hindlll/BamHI digestion the 4.3 kb band was the only rearranged 
fragment detected and this was at half the intensity of the normal 2.5 
kb band^ Similarly Xbal digestion revealed only one rearranged fragment 
(result not shown) but Kpnl and Sail which map sites further downstream 
than the Hindlll site 3.0 kb 3' to c-myc detected two tumour-specific 
bands.
These results indicated the presence of three c-myc alleles in 
tumour T5: two rearranged and one of normal gross structure (Fig.4.5).
One alteration was between the PstI and BamHI sites 0.5 and 2.1 kb 3 
to exon 3, and the other was between the Xbal and Hindlll sites £.*> and 
3.0 kb 3' to exon 3. Since only one additional Xbal fragment was 
present, one of the mutant alleles appeared to retain the normal Xbal
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site 2.5 kb 3 to exon 3. This indicated that the tumour-specific Xbal 
site was on the mutant c-myc allele which was rearranged 5' to the 
normal Xbal site, corresponding to the allele with the largest Hindlll 
fragment. Further clarification of these structures would require 
cloning of the rearranged DNA.
4.3 DISCUSSION
Analysis of c-myc rearrangements revealed a variety of modes of 
alteration at the c-myc locus (Table 4.1; Fig.4.5). These include cases 
with a small degree of amplification (T5, T9), others due to proviral
insertions (T7, T8, T24), and a case with a 3' rearrangement (T5). All 
rearrangements studied left the c-myc coding exons 2 and 3 intact, 
consistent with the suggestion made with respect to v-myc genes, that 
the entire myc product is required for transforming activity (Chapter 
3). Similarly, no known c-myc rearrangement in human or murine tumours 
truncates the coding domain (Marshall, 1985).
4.3.1 Insertion in intron 1 in tumour T24
The insertion in intron 1 in tumour T24 appears to be a truncated 
FeLV provirus retaining a 5' LTR in the same orientation as c-myc and 
is reminiscent of ALV and REV promoter insertions at c-myc in chicken 
bursal lymphomas, although in these cases it is usually a 3 'LTR which 
is retained (Hayward et al, 1981; Shih et al, 1984; Swift et al, 1985). 
Viral promoter insertion may be favoured by integration in intron 1 
since this displaces the normal cellular gene promoter region.
More than 70% of ALV and REV insertions in the chicken c-myc locus 
are in intron 1 (Shih et al, 1984; Swift et al, 1985; Robinson & 
Gagnon, 1986) which may signify that this integration site favours 
activation of the gene, perhaps by displacing exoh 1 and upstream 
regulatory sequences (Saito et al, 1983; Piechaczyk et al, 1985;
Bentley & Groudine, 1986a). In contrast, most insertions at the 
feline or murine c-myc gene are upstream of exon 1 (Fig.4.5; J.
Mullins, pers. comm.; Corcoran et al, 1984; Selten et al, 1984;
O'Donnell et al, 1985). It is possible that different regions are
locally susceptible to proviral insertion in these species, perhaps due 
to an open chromatin structure (Shih et al, 1984; Robinson & Gagnon, 
1986), This is not to argue that they are fortuitous common 
integration sites irrelevant to oncogenesis, since some studies show
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ALV, MuLV and FeLV infected, non-transformed tissues not to display 
specific integration patterns (Fung et al, 1982; van der Putten et al, 
1979; Casey et al, 1981).
Many avian proviruses at the c-myc locus, like the T24 insert, are 
deleted to some extent (Fung et al, 1981; Swift et al, 1985; Robinson & 
Gagnon, 1986). Most commonly, internal sequences near to the 5' LTR are 
deleted, perhaps including a splice donor site and viral RNA packaging 
signals (Robinson & Gagnon, 1986). Since some tumours contain only a 
deleted provirus, it was suggested that deletions may be selected if 
they prevent expression of viral antigens, allowing the tumour to 
escape the host's immune response (Payne et al, 1981; Neel et al, 
1981).
4.3.2 Upstream insertions in tumours T7 and T8
The apparently intact FeLV proviruses upstream of c-myc in tumours 
T7 and T8 are oriented away from the gene, similar to the enhancer 
insertions found in many MuLV-induced thymic lymphomas and some 
ALV-induced bursal lymphomas (Corcoran et al, 1984; Selten et al, 1984; 
Li et al, 1984; Steffen, 1984; Payne et al, 1982). Why are upstream 
proviruses predominantly in this orientation? An explanation proposed 
for similar findings on MMTV insertions at int-1 and int-2 is that 
since enhancers may act preferentially on proximal promoters, then 
this orientation may be required to juxtapose the 5' LTR enhancer to 
the cellular gene promoters (Nusse et al, 1984; Dickson et al, 1984). 
If the provirus was in the other orientation then a viral promoter 
would lie between the enhancer in the 3' LTR and the cellular gene 
promoter.
Upstream insertions may superimpose viral LTR control over the c-myc 
promoters, but may also disrupt regulatory elements identified upstream 
of the mammalian c-myc gene (Remmers et al, 1986; B. Whitelaw et al, 
pers. comm.) as has been proposed in murine plasmacytomas where the 
c-myc gene carries an upstream chromosomal translocation breakpoint 
(Yang et al, 1985).
4.3.3 Alteration at the 3' end of c-myc in tumour T5
Tumour T5 presents a complex 3' rearrangement which is atypical of 
those recorded in retrovirus-associated lymphomas of other species, 
since it does not seem to be directly virus-induced. The events 
generating the two rearranged alleles are not known but must involve
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duplication and two structural alterations. This structure is 
remarkably like that found in the human leukaemic T cell line Hut78 
which carries two copies of a mutant c-myc allele rearranged 0.6-1.0 kb 
3' of exon 3 (Saglio et al, 1986). In this case the two mutant alleles 
appear to result from duplication of the entire chromosome. 
Unfortunately, tumour T5 could not be analysed cytogenetically as the 
cells could not be established in culture (D. Onions, pers. comm.).
Although the origin of the rearranged DNA 3' to c-myc is unknown, 
recent studies of human T cell leukaemias suggest possibilities for 
further study. Chromosomal translocations have been identified which 
abnormally join the a-chain locus of the T cell antigen receptor (TCR)
3' to c-myc (Erikson et al, 1986; Shima et al, 1986). These
rearrangements are similar to variant translocations in Burkitt's 
lymphomas which join Ig light chain genes 3' to c-myc (Taub et al, 
1984b; Hollis et al, 1984). 3' rearrangements may deregulate c-myc
expression through a long range mechanism, perhaps involving TCR or Ig 
gene enhancers which may be highly active in T or B cells respectively. 
Although no linkage between exogenous FeLV sequences and the T5 
rearranged c-myc fragments was detected, a few FeLV proviral elements 
were present (J. Neil, pers. comm.). It is an intriguing possibility 
that chromosomal rearrangement at c-myc and an independent FeLV
insertion at another cellular locus were involved in the genesis of the 
tumour.
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TUMOUR FIELD OR FeLV FeLV FeLV DISEASE c-myc
CASE EXPERIMENTAL STATUS COPY STRAIN LATENCY ALTERATION
CASE NO. (months)
T9 field - 0 / / amplification
T7 + 11 / / 5' insertion
T8 experimental + >50 Rickard 6 5 ’ insertion
T5 II + (2) Glasgow-1 24 3' alteration 
+ amplification
T24 II + ND Glasgow-1 9 5' insertion
Table 4.1. Characteristics of feline tumours which contain a 
rearranged c-myc gene.
(/) = not applicable.
ND = not determined.
FeLV status refers to the presence of integrated exogenous 
FeLV proviruses detected by a U3 hybridisation probe. The copy 
number of proviruses was assessed by the number of discrete 
FeLV-cellular DNA junction fragments detected with the U3 probe 
on Kpnl digested tumour DNA (Kpnl cuts in the R region of the 
LTR of a typical FeLV provirus). This analysis detected two 
discrete bands in tumour T5 DNA, but apparently not any proviral 
internal bands, with Kpnl digestion, suggesting that the FeLV 
sequences present did not represent intact proviruses (J. Neil, 
pers. comm.).
T7 and T5 contained a monoclonal pattern of integrated FeLV 
sequences, judged by the equal intensities of the junction 
fragments detected with the U3 probe. The equal signal 
intensities of the normal and rearranged c-myc bands in T7, T8 
and T24 indicated that these were clonal tumours (section
4.2.1). Clonality could not be assessed for T9 using these 
probes.
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Fig.4.1. Origin of probes used to map c-myc rearrangements 
in feline tumours.
The top two lines represent overlapping clones of the 
feline c-myc gene (/^SPF62, Mullins et al, 1984; pFMC-1, 
Chapter 3). The next line shows a restriction enzyme map of 
the c-myc locus with exons 1-3 represented as boxes from left 
to right.
Probes: 1, SraaI/700 bp; 2, BglIl/Pstl/500 bp; 3, 
HindIIl/BglIl/645 bp; 4, Pstl/EcoRI/700 bp derived from pCT4 
v-myc clone (Neil et al, 1984). Restriction enzyme 
abbreviations: Ba, BamHI; B, Bglll, H, Hindlll; R, EcoRI;
S ,  S a i l .
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Fig.4.2. Southern blot analysis of tumour T24 and control 
kidney DNA using probe 4 (Fig.4.1).
The different signal intensities between tumour and control 
lanes result from variations in DNA concentrations. 
Restriction enzyme abbreviations: H, Hindlll; E, EcoRI;
K, Kpnl; P, PstI.
M, Hindlll-digested/\DNA, ^^P-labelled markers.
231
9-4 
67
4 4 — 1
2 3 
2 0
057-
Sall+ SqU+ SqU+ SqLI+
Bglll Psfl Kpnl BamHI PstI Pstl+ Pstl+ Pstl +
M r T r T r T T T   Kpnl BamHI Bqlll
■ I M T C T C T T  T C
*
# "  -
iitr
Fig.4.3. Southern blot analysis of control kidney (C) and 
tumour T24 DNA using probe 1 (left) and probe 2 
(right) (Fig.4.1).
M, Hindlll-digested /\DNA, ^^P-labelled markers.
Probe 2 gave a background signal in all lanes which may be 
due to a moderately repetitive element in the intron 1 region 
from which probe 2 originated. The stronger smear in the <1 
kb range in tumour lanes may be due to hybridisation to PstI 
satellite bands and to RNA present in the DNA preparation.
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Fig.4.4. Southern blot analysis of control kidney (C) and 
Tumour T5 (T) DNA using probe 3 (Fig.4.1).
M, Hindlll-digested /\DNA ^^P-labelled markers.
The reduced signal in the high molecular weight range 
results from poorer transfer of large DNA fragments.
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Fig.4.5. Structures of rearranged c-myc genes in tumours.
The central line represents a restriction enzyme map of the 
normal c-myc locus with exons 1 - 3  shown as black boxes, 
from left to right. To aid interpretation, a typical 
restriction enzyme map of an FeLV provirus and that of a 
truncated provirus retaining a 5' LTR are shown at the top 
and bottom of the diagram for comparison to the rearranged 
structures. Relative transcriptional orientations of c-myc 
and FeLV sequences are shown by horizontal arrows.
Restriction enzyme abbreviations: B, BamHI; B2, Bglll; H, 
Hindlll; K, Kpnl; P, PstI; R, EcoRI; S, Sail; 81, SstI;
X, Xbal.
CHAPTER FIVE
EXPRESSION OF THE c-myc GENE IN NORMAL AND TUMOUR CELLS
5.1 INTRODUCTION
It was necessary to study the structure and expression of the 
transcription unit of the normal feline c-myc gene, so that comparison 
could be made with tumour cases containing rearranged c-myc loci. This 
could provide clues as to how expression may be altered possibly 
causing oncogenic activation of the gene in these tumours.
Previous reports showed that the human and murine c-myc genes 
produce transcripts from two promoter regions, PI and P2, separated by 
~150 bp at the 5' end of exon 1 (Watt et al, 1983b; Stewart et al, 
1984a). The sequence of the feline c-myc gene identified similar PI and 
P2 regions, hence it was of interest to investigate the presence of 
corresponding transcripts. Also, two possible polyadenylation sites had 
been identified at the 3' end of exon 3 in the human, mouse, chicken 
and cat genes, but investigation of their function had previously been 
reported only for the human gene (ar-Rushdi et al, 1983 ; Taub et al, 
1984b).
This chapter also includes an examination of how expression of the 
feline c-myc gene might be altered by rearrangements in tumours. Some 
experiments were prompted by reports on altered c-myc genes in tumours 
of other species. First, it was reported that rearrangement of the 
c-myc gene may elevate its expression (Hayward et al, 1981; Alitalo 
et al, 1983; Erikson et al, 1983). This has been interpreted as 
evidence that c-myc expression has become deregulated in a way that 
contributes to oncogenesis. Also, it has been proposed that in human 
and mouse B cell lymphomas, rearrangements of the c-myc gene which 
leave the transcription unit intact may disturb the normal balance in 
relative abundance of the PI and P2 RNAs (Taub et al, 1984a; Yang et 
al, 1985). An elevated ratio of PI to P2 RNAs may be characteristic of 
these rearrangements, and has been suggested to reflect oncogenic 
activation of the gene, perhaps under the control of d s -acting 
elements present in the rearranged DNA and/or by disruption of control 
regions of the c-myc locus (Remmers et al, 1986). In contrast, in 
tumours where rearrangements disrupt exon 1 of the c-myc gene it has 
been suggested that altered c-myc RNAs are produced which have abnormal
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properties, perhaps through loss of exon 1 regulatory functions (Saito 
et al, 1983; Piechaczyk et al, 1985).
Analysis of the limits of the transcription unit of the feline c-myc 
gene involved SI nuclease mapping of RNA from normal and tumour cells 
with probes derived from appropriate regions of clones of the normal 
gene, as predicted from sequence data.
5.2 MATERIALS AND METHODS
All procedures were as described previously except the following:
5.2.1 Materials.
DMSO/dye: 30% (w/v) dimethylsulphoxide, ImM EDTA, 0.05% (w/v) of
each of xylene cyanol and bromophenol blue (stored at 4°C).
SI nuclease mapping hybridisation solution: 80% (v/v) formamide, 40mM 
PIPES buffer pH 6.4, 400mM NaCl, 1 mM EDTA (stored at -20°C).
SI nuclease digestion solution: 200mM NaCl, 4.5mM zinc acetate, 80mM 
sodium acetate pH4.4, 20pg/ml calf thymus DNA (stored at -20°C).
Glass microcapillary tubes were coated internally before use with 
repelcote, and were treated with DEP to inactivate possible 
contaminating RNAses,
5.2.2 Methods.
Preparation of 5' and 3' end-labelled, single-stranded probes.
Fig-5.1 indicates the c-myc-derived SI nuclease mapping probes used 
and Table 5.1 summarises the protocols for their preparation and use.
Probe A . The Smal 700 bp fragment was sub-cloned into pUC8 to 
generate the plasmid pS700. lOpg aliquots of pS700 were digested with 
Smal then treated with bacterial alkaline phosphatase, and 5' 
end-labelled with polynucleotide kinase and îT-^^P-ATP (Chapter 2). 
Unincorporated nucleotides were removed by gel filtration through a 
Sephadex G50 column. The labelled Smal 700 bp insert was purified by 
preparative agarose gel electrophoresis.
Strand-separation : the purified fragment was dissolved in denaturing 
DMSO/dye mixture, heated at 90°C for 4 minutes to dissociate the DNA 
strands, then the tube was plunged immediately into iced water 
according to Maniatis et al (1982). The mixture was loaded onto a 5-g 
polyacrylamide strand-separating gel (40 x 20 cm x 1.5 mm) and 
electrophoresed for 18-20h at 300V. The separated strands were located 
on the gel by autoradiography (Fig.5.2). Both strands were eluted from
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the gel by standard methods (Chapter 2). It was empirically determined 
by SI nuclease analyses that the upper band contained the antisense 
strand (i.e. complementary to the RNA).
Probe B was prepared by essentially the same method as for probe A, 
except that strand-separation was performed on an 8% polyacrylamide gel 
at 200V for 18h. The upper band was determined to contain the antisense 
strand.
Probe C . The 3' ends of probe C (Hindlll/Bglll 650 bp) were labelled 
using Klenow polymerase (Chapter 2). 15pg of a plasmid (obtained from 
R. McFarlane) containing the probe C fragment, digested with Hindlll 
and Bglll, was dissolved in 15pl of TE pH8.0. This was made to a volume 
of 50pl containing ImM DTT, ImM spermidine, Ix Klenow reaction buffer, 
10 units of Klenow polymerase and 60pCi of each of all four 
a-32p-iabelled dNTPs. The reaction was incubated at room temperature 
for 15 minutes, then lOpl of chase solution (0.5mM of each 
non-radioactive dNTP) added, and the reaction incubated for 20 minutes 
longer. Unincorporated nucleotides were removed and the labelled probe 
fragment isolated as described for probe A. The strands were separated 
on a 5% polyacrylamide gel by electrophoresis at 320V for 20h. The 
lower band contained the antisense strand.
SI nuclease analyses.
20pg samples of total cellular RNA were added to a lOpl volume of
hybridisation solution with lOpg carrier E_^  coli rRNA and lOOng of the
relevant probe A, B or C. (A titration experiment with probe A 
determined that lOOng should ensure conditions of probe excess; section
5.3.1). The reactions were performed in sealed glass microcapillary 
tubes which were completely immersed in a water bath at 95°C for 5 
minutes then immediately transferred into a water bath at the 
appropriate temperature for overnight incubation (Table 5.1). Next day 
the tubes were removed, carefully opened, and the contents ejected into 
lOOpl of ice-cold SI nuclease digestion buffer. 100 units of SI 
nuclease were added and the reaction incubated at 37®C for 0.5h.
Reactions were stopped by placing on ice and adding 4pl of 0.5M EDTA. 
Carrier yeast tRNA (20pg) was added and the mixture was phenol
extracted and ethanol precipitated. Samples were redissolved in 4pl of 
formamide/dye, heated at 95°C for 5 minutes then electrophoresed on 6% 
(probes A and B) or 4% (probe C) polyacrylamide/7M urea gels (Chapter
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2), at 1200-1500V. Gels were fixed in 10% (v/v) acetic acid/10% (v/v) 
methanol, dried, then autoradiographed at -70°C.
5.3 RESULTS
5.3.1 Determination of optimum hybridisation conditions. (Table 5.1).
Various factors influence the formation and stability of DNA/RNA 
hybrids in SI nuclease analyses (Favoloro et al, 1980), including the 
size of the hybrid formed and the %GC base-pairing between the probe 
and RNA. Ideally, the hybridisation temperature should be as high as 
possible to minimise non-specific annealing and to reduce formation of 
intra-molecular secondary structures, but not so high that the DNA/RNA 
hybrids are unstable.
Probe A . It was important to determine the optimum hybridisation 
temperature and the conditions for probe excess for probe A, as this 
was to be used for quantitative analysis of the relative abundances of 
the PI and P2 5' end discontinuities:
Temperature : RNA from tumour 86800 which has no detectable myc
alteration, was hybridised with probe A over a range of temperatures
(51-67°C) (Fig.5.3). Probe A detected PI and P2 RNAs as SI nuclease 
protected bands of 286 and 105 nucleotides. The ratio of PI to P2 
bands detected varied from 6:1 at 51°C to 3:1 at? 63°C. At 67®C no P2 
signal could be detected, even with prolonged autoradiography, 
suggesting that 67°C incubation destabilised the shorter P2 hybrids. I
performed subsequent analyses at 59°C to optimise the P2 signal.
Probe concentration: Using probe A to analyse tumour 86800 RNA, the
P1/P2 ratio detected was found to vary with the amount of probe
(Fig.5.4). A constant ratio was detected with >50 ng of probe. In 
subsequent analyses, I used 100 ng of probe per reaction to ensure 
conditions of probe excess for other samples since none seemed to 
contain markedly higher levels of c-myc RNA than tumour 86800.
Probe B was used under the conditions determined for probe A, since 
it was expected to detect PI hybrids of intermediate length and 
similar %GC base-pairing as the PI and P2 bands detected with probe A.
Probe C was used to map RNA at the 3* end of exon 3. (Fig.5.5). Only 
one major band of 435 nucleotides was detected over the chosen 
temperature range. Above 49®C no obvious bands were detected,
suggesting that this temperature destabilised hybrids. I performed
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later analyses at 41°C.
5.3.2 5' and 3' limits of the c-myc transcription unit (Fig.5.6).
Probe A detected PI and P2 5' discontinuities of 286 and 105
nucleotides in RNA from normal feline embryonic fibroblasts and tumour 
86800. Probe B was used as an independent confirmation for PI hybrids 
which were detected as a series of bands of ~138 nucleotides (see 
section 5.3.3).
Probe C detected a major band (~435 nucleotides) in normal 
fibroblast RNA mapping ~25 nucleotides 3' to the most downstream 
polyadenylation signal (Fig.5.8). Additional fainter bands were 
detected below this major band, one of which (~310 nucleotides) mapped 
~15 nucleotides 3' to the upstream polyadenylation signal. However, the 
strongest of these minor bands was only ~10 nucleotides shorter than 
the major band, and could result from excessive SI nuclease digestion 
or stem-loop formation.
5.3.3 Mapping PI and P2 RNA 5 ' discontinuities to the exon 1 sequence 
PI and P2 bands were precisely located against sequence ladders of
probes A and B, and mapped to consensus RNA cap sites 24 and 27 
nucleotides respectively downstream from TATA boxes (Fig.5.7). The 
broad PI band mapped over three nucleotides at the expected RNA start 
site, and included a fainter band seven nucleotides shorter, present in 
all normal and tumour RNAs studied. This minor band may represent 
another RNA species with a different 5 ' terminus since it maps to a 
sequence with some homology to an RNA cap site. However, since it is so 
close to the major band detected, it may result from excessive SI 
nuclease digestion or secondary structure formation. The broad P2 band 
mapped over four nucleotides at the predicted P2 consensus cap site.
5.3.4 Levels of expression of c-myc in normal and tumour cells.
Northern blot analyses with a myc probe of RNA from tumours with or
without c-myc rearrangements, others containing an FeLV/myc virus or
with no apparent myc alteration, and from normal cells are shown in
Fig.5.9. Levels of c-myc RNA were not markedly elevated in tumours T7,
T8, T5 and T24 with c-myc rearrangements compared to tumours with no
myc abnormality. Levels were greater than in normal embryo fibroblasts 
and mitogen stimulated thymocytes, but did not show the dramatic 
increase observed for a myc gene expressed from a recombinant FeLV/inyc 
provirus.
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5.3.5 Normal c-myc RNA structure in tumours T7, T8 and T5.
Northern blot analysis detected c-myc RNA of normal size (2.2-2.4 
kb) in tumours T7, T8 and T5, in accord with Southern blot mapping data 
showing that the rearrangements in these cases leave the normal
transcription unit intact (Fig.5.9; Chapter 4). In view of the
proximity of the T7, T8 and T5 rearrangements to the c-myc
transcription unit, I undertook SI nuclease mapping to investigate
possible subtle changes to the termini of c-myc transcripts. Using 
probe A, PI and P2 5' discontinuities were detected in cases T7, T8 and 
T5 and in tumours without c-myc rearrangement, which were co-terminal 
with those in normal fibroblasts and thymocytes.
Normal 3' ends were detected in all tumours studied regardless of
c-myc rearrangement (Fig.5.lOB). Thus, in tumour T5 the 3' alterations 
to c-myc on the two mutant alleles do not appear to perturb formation 
of the normal transcript 3 ’ end.
5.3.6 Loss of exon 1 in tumour T24 c-myc transcripts.
Northern blot analysis showed that the c-myc RNA in tumour T24 was 
~200 nucleotides shorter than normal (Fig.5.9), and SI nuclease mapping 
detected no PI and P2 bands, consistent with Southern blot data showing 
that the insertion displaced exon 1 (Chapter 4). Interestingly, lack of 
PI and P2 bands indicated that there was no detectable RNA from the 
unrearranged c-myc allele in this tumour. Since Northern blot analysis 
detected a c-myc RNA band, and since probe C (Fig.5.lOB) detected a 
normal RNA 3 ' end, this RNA was probably derived from the mutant, not 
the normal, allele (discussed in Chapter 6).
5.3.7 Varying ratios of PI to P2 RNAs in tumours and normal cells.
The P1/P2 ratios in the tumour series varied considerably (Fig.5.9; 
Table 5.2). In normal fibroblasts and in alimentary lymphosarcoma 
87416, approximately equal levels of PI and P2 transcripts were
detected. In ConA stimulated normal thymocytes and nine T cell tumours 
a higher ratio was detected. In normal thymocytes the ratio was 2:1 
but in tumours this varied from 3.1:1 (case 86800) to 19.6:1 (case 
89407 ). Tumours T7, T8 and T5 displayed ratios in the highest range 
(17.9:1, 17.0:1 and 13.6:1 respectively). T cell tumours without
detectable alteration in the 20 kb region around the c-myc locus 
screened by Southern blot analysis displayed a range of ratios , which 
in some cases (T21 and 89407) were comparable to those in tumours
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carrying a c-myc rearrangement. No correlation was observed between the 
ratio and the presence or absence of FeLV.
The P1/P2 ratio in feline thymic tumours was markedly higher (in the 
range 3:1 to 20:1) than that recorded for human and mouse B cell 
lymphomas with or without c-myc rearrangements (generally < 2:1; Taub 
et al, 1984b; Yang et al,, 1985). The differences may result partly 
from different SI nuclease analysis conditions, since my results in 
section 5.3.1 show the importance of standardising conditions. However, 
the differences may also reflect genuine species and/or cell type 
variations.
5.4 DISCUSSION
5.4.1 The transcription unit of the feline c-myc gene.
SI nuclease mapping supports the predicted locations of signals for 
initiation and polyadenylation of transcripts of the feline c-myc gene. 
The PI and P2 5' discontinuities mapped to promoter-1ike sequences, and 
although unequivocal confirmation that these represent RNA start sites
and not splice acceptor sites would require primer extension studies,
this view is supported by other evidence:
(1) The sequences around the PI and P2 sites closely match the
consensus for TATA boxes and RNA cap sites (Fig.5.7) but do not conform 
closely to splice acceptor signals (Mount, 1982).
(2) The PI and P2 sites were homologous to sites identified in the
human and mouse c-myc genes by SI nuclease mapping (Watt et al, 1983b; 
Stewart et al, 1984a), The human PI site has been confirmed by primer 
extension analysis (Watt et al, 1983b).
(3) The same PI and P2 SI nuclease protected bands were detected in two 
tumours with FeLV insertions 0.5 and 2.5 kb upstream of exon 1 (section 
5.3.5) suggesting that the insertions lie outside the transcription 
unit.
81 nuclease mapping of the 3 ' end of exon 3 suggested that the most 
3* of the two possible polyadenylation signals is used predominantly 
as seems to be the case in the human and chicken c-myc genes (ar-Rushdi 
et al, 1983; Taub et al, 1984a; Nottenburg & Various, 1986). Other 
elements near the AATAAA signal also may be important to form the 3 
end of eukaryotic transcripts. McLauchlan et al (1985) identified a 
consensus sequence located 30 nucleotides 3 ’ to the AATAAA site in 70-^
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of genes examined, and a closely matched sequence (AGTGTTTT) occurs 41 
nucleotides 3' to the most 3' AATAAA signal of the feline c-myc gene 
(Fig.5.8).
5.4.2 Significance of the PI and P2 c-myc transcripts.
No differential function is known for the PI and P2 transcripts of 
the mammalian c-myc gene. The exon 1 leader of the RNA may adopt 
secondary structures, some of which may differ between the PI and P2 
RNAs (Battey et al, 1983), but their physiological relevance is 
unknown.
Since PI and P2 RNAs are reported to be equally stable (Piechaczyk 
et al, 1985) variations in the P1/P2 ratio suggest that they may be 
differentially transcribed. My results suggest that the P1/P2 ratio may 
differ in a tissue-specific fashion, as the ratio in fibrobasts was 
less than half that in thymocytes (Table 5.2). Also, the ratio was 
considerably higher in T-cell tumours than in an alimentary 
lymphosarcoma (probably a B-cell tumour; Jarrett, 1984). Similarly,
variations in the ratio in different mouse tissues have been recorded 
(Stewart et al, 1984a).
5.4.3 Rearranged c-myc genes: levels of expression.
Levels of c-myc RNA do not differ markedly in feline tumours with 
or without rearrangement of the gene, although tumour T5 carrying a 
small degree of amplification of the c-myc gene has slightly higher 
levels. However, levels are higher than in normal cells (fibroblasts or 
thymocytes) as also reported for chicken and mouse tumours with 
proviral insertions at the c-myc gene (Hayward et al, 1981; Payne et 
al, 1982; Corcoran et al, 1984; Selten et al, 1984).
It is difficult to assess the significance of the levels of c-myc 
RNA in the tumours with rearrangements of the gene since an appropriate 
control cell is subject to arbitrary choice. Neither normal cells nor 
tumours without an altered c-myc gene may be appropriate. Perhaps the 
ideal control would differ from the tumour cells with the c-myc 
rearrangement only in the structure of its c-myc gene. Since the 
tumours may arise from an infected cell at an unknown point in the 
T-cell developmental pathway, the precise control cell would not be 
available.
5.4.4 Structure of transcripts from rearranged c-myc genes
Of the feline tumours studied, only case T24 contained an unusual
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c-myc RNA, 200 nucleotides shorter than normal, apparently resulting 
from displacement of exon 1. Loss of exon 1 in rearranged c-myc genes 
in human and mouse tumours has been reported to increase c-myc RNA 
levels by increasing RNA stability, although contrary results were 
recorded for a chicken lymphoma (Piechaczyk et al, 1985; Rabbitts et 
al, 1985; Linial et al, 1985). In tumour T24, c-myc RNA levels were not 
any higher than in tumours where the c-myc transcription unit remained 
intact (Fig.5.9).
An intriguing possibility is that the T24 insert represents an 
intermediate in the pathway to myc transduction by FeLV, in accord with 
models of transduction (Swanstrom et al, 1983). As the insert 
apparently consists of a 5' FeLV LTR and internal sequences 5' to the 
gag gene which by analogy with MuLV may include viral RNA packaging 
signals (Mann et al, 1983), then packageable insert-c-myc fusion 
transcripts could be generated. To test this hypothesis, I hybridised 
a Northern blot of tumour T24 RNA with an FeLV U5 probe. Unfortunately, 
a U5-hybridising band corresponding to the c-myc band could not be 
identified due to a background smear of U5-hybridising RNA (not shown). 
However, the possible existence of FeLV-c-myc fusion RNAs could be 
investigated by cDNA cloning the aberrant c-myc RNA from tumour T24. A 
similar proviral insertion in a chicken lymphoma was shown to produce a 
new myc-transducing virus when filtered tumour extract was shown to 
induce tumours with short latency in young chickens (Robinson & Gagnon, 
1986) .
5.4.5 Varying ratios of PI to P2 RNAs in tumour and normal cells
A considerably higher ratio of PI to P2 RNAs was detected in feline 
thymic tumours . carrying a c-myc rearrangement than in normal 
fibroblasts or thymocytes, in accord with reports that an elevated 
P1/P2 ratio may be characteristic of rearranged c-myc genes in human 
and murine tumours (Table 5.2; Taub et al, 1984a; Hollis et al, 1984; 
Yang et al, 1985). Tumours T7 and T8 are the first examples where this 
has been recorded for provir al insertions at the c-myc locus, to 
extend the previous findings for chromosomal rearrangements.
It might be speculated that enhancers in the LTRs of upstream 
proviruses preferentially activate transcription of PI rather than the 
more downstream P2 promoter, since some enhancers seem to act on 
proximal rather than distal promoters (review: Lang & Spandidos, 1985).
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It is less clear how the 3' rearrangement in tumour T5 might cause a 
high P1/P2 ratio, although 3' rearrangements in Burkitt's lymphomas 
have also been reported to be associated with a high P1/P2 ratio 
(Hollis et al, 1984; Taub et al, 1984b). Perhaps the overall chromatin 
structure of the locus becomes altered.
My results indicate complexity in control of differential expression 
of PI and P2, since several tumours diplay a high P1/P2 ratio in the 
absence of detectable c-myc rearrangement. This could result partly 
from tissue-specific variation (section 5.4.2). It is also possible 
that as yet undetected point mutations in regulatory elements have the 
same influence as gross rearrangements on the P1/P2 ratio. If c-myc 
expression is assumed to be controlled by the products of other genetic 
loci, then alterations to distant, cis-acting elements or trans-acting 
factors may disturb the ratio. Similar ideas were invoked to explain 
the reported elevation of c-myc expression which accompanied 
rearrangement at the pvt-1 locus, which is >72 kb distant from c-myc, 
in murine plasmacytomas (Cory et al, 1985; Graham et al, 1985).
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End-labelled 
Probe/size (bp)
Strand-separating 
gel: % polyacryl.
Antisense 
DNA strand
Sma/700
upper
SX2/198
upper
H3B2/645
lower
% GC of DNA/RNA 
hybrids predicted 
/size (bp):
PI
P2
al
a2
Hybridisation 
temp. optimum
Analytical gel:
% polyacryl.
58%/285
67%/105
69%/138
59°C 59°C
33%/310
29%/435
41°C
4%
Table 5.1 Summary of protocols for preparation and use of 5' 
and 3' end-labelled, single-stranded feline c-myc 
probes for SI nuclease mapping (section 5.3.1).
Abbreviations :
probes: Sma, Smal; SX2, Sau3A/XhoII; H3B2, Hindlll/Bglll. 
polyacryl., polyacrylamide
DNA/RNA hybrids predicted: PI, 5' most RNA start site
P2, 3' most RNA start site
al, 5 ' most polyadenylation site
a2, 3 ' most polyadenylation site
F
Sm X ,Sm
---------1------------ f -1 1 —r —
H
V7V//À
L i _ )  'EXON I EXON 3
a B2
500 bp
Fig.5.1. Origin of c-myc-derived probes used for SI nuclease 
mapping RNA from feline cells.
Probe A encompassed the PI and P2 promoter-like elements at 
the 5 ’ end of exon 1, and probe B should be specific for the 
PI region. Probe C encompassed both putative polyadenylation 
signals {"a") at the 3' end of exon 3. Coding sequences are 
indicated by cross-hatching and non-coding by open boxes.
Restriction enzyme abbreviations: B2, Bglll; H, Hindlll;
S, Sau3A; Sm, Smal; X, XhoII.
0 —
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Fig.5.2. Strand-separation of 5' end-labelled probe A. 
(Table 5.1; section 5.2.2)
The separated strands of the 5' end-labelled probe A 
fragment were located on the gel by autoradiography at room 
temperature for 15 minutes using an intensifying screen.
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Fig.5.3. Determination of the optimum hybridisation
temperature for detection of c-myc PI and P2 RNA 
5' discontinuities using SI nuclease mapping 
probe A. (Section 5.3.1; Table 5.1).
The ratio of PI to P2 hybrids detected for each temperature 
was guantitated by densitometry, and the results plotted 
graphically as shown below the autoradiograph. Since in some 
samples the ratio detected varied greatly, autoradiographs 
were exposed for the minimum time necessary to permit 
densitometric analysis of the fainter P2 band. This minimised 
bias of results due to disproportionate variation of signal 
intensity with exposure time.H'l'^ p'-ctence/dfc^ fince if ^A.
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Fig.5.4. Variation in the ratio of c-myc PI to P2 RNA
5'discontinuities detected by SI nuclease mapping 
using different quantities of probe A.
(Section 5.3.1; Table 5.1).
The ratio detected increased using < 50ng of probe but was 
constant with > 50ng of probe, as shown graphically below the 
autoradiograph.
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Hybridisation temp. (°C)
41 45 49 53
+ +  —  +  — +  — +  —
PROBE
H3B2
MAJOR
3'END
~435nt
-5 0 7
-5 0 4
-434
-2 6 7
-2 3 4
H in d u
_J___
EXON 3
Q Q B g in
H3B2 (6A5nt)
Fig.5.5. Determination of the optimum hybridisation 
temperature for detection of c-myc RNA 3' 
discontinuities using SI nuclease mapping probe C 
(Section 5.3.1; Table 5.1).
The origin of probe C is shown below the autoradiograph 
with exon 3 coding regions shown by cross-hatching and 
non-coding regions by an open box. The %GC base-pairing for 
RNAs mapping to the two predicted polyadenylation signals 
("a") was only "*30%, hence, the optimum hybridisation 
temperature was determined using a low temperature range.
M, Haelll-digested pBR322, ^^P-labelled markers.
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Fig.5.6. Summary of RNA 5' and 3' discontinuities detected 
with SI nuclease mapping probes A, B and C 
(Table 5.1).
A and B show the respective results with 5' end-labelled 
probes A and B, and C shows results using 3' end-labelled 
probe C. Lanes: 1 and 5, FEA embryo fibroblast RNA; 2 and 3, 
tumour case 86800 RNA; 4 and 6, controls with carrier RNA and 
no sample RNA; M, markers were for A and B, Haelll-digested 
0X174, and for C, HinfI-digested pBR322 labelled with P.
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F i g . 5.7. PI and P2 RNA 5' discontinuities detected by SI 
nuclease analyses map to consensus promoter 
sequences.
Top: PI and P2 hybrids detected with probes A and B in FEA 
normal embryo fibroblasts (RNA lanes) were electrophoresed 
alongside chemically-cleaved sequence ladders of probes A and 
B respectively (lanes G, G+A, T+C, C). To aid 
interpretation, the origins of the probes are shown at the 
top, and the sequences of probes A and B are shown to the 
left of each autoradiograph.
Bottom: The sequences of the PI and P2 regions are aligned 
with consensus TATA box and RNA cap site sequences 
(Breathnach & Chambon, 1981).
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CGTGAATTCTCACTTGTT ACT AAGQQAAAQTAAGGAAAAAGCTTCCTTCTCACA6AACTGTAGCAACTCC 
TCATATCTGAACTTGTTTCAAATGCATGQTCAAGTGCAACCTCACAACCTTGQCTGGGTCTTAGGATTGA
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GTGTTTTGTTTTTCTTGCCTTTTTTTTCTATTTTCTTTTCATCAATTCCAATTAACAGAATTTGGCCCTC
Fig.5.8. Sequence of the 3' end of c-myc exon 3 showing the 
location of the major RNA 3' discontinuity detected 
by SI nuclease mapping.
Consensus polyadenylation signals (AATAAA) are enclosed in 
boxes and a sequence similar to the consensus YGTGTTYY, where 
Y = pyrimidine (McLauchlan et al, 1985) is underlined. The 
location of the 3' RNA discontinuity detected by SI nuclease 
mapping is marked by a vertical arrow.
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Fig.5.9. Northern blot analyses of RNA from feline tumours 
and normal cells using an FeLV v-myc probe.
Lanes: tumours carrying a rearranged c-myc gene, T7, T8,
T5, T24; tumours containing an FeLV/myc virus, T3, F422, Til, 
T17; tumours with no apparent myc abnormality, 89407, T18, 
89960, FL74; normal cells, FEA embryo fibroblasts.
Act. thym., mitogen (ConA) activated n o r m a l  thymocytes.
Sizes were estimated by comparison with Hindlll-digested 
XDNA, 32p_iabelled markers (not shown).
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Fig.5.10. SI nuclease analyses of c-myc RNA in normal cells 
and in tumours with and without rearrangement of 
the c-myc locus.
Top: quantitative analysis of the relative amounts of PI and 
P2 transcripts, using probe A.
Bottom: Analysis of 3' discontinuities with probe C.
RNA samples were: ANT, mitogen activated normal thymocytes; 
FEA, normal embryo fibroblasts; TIB, 86800, T23, T19, T21, 
89407, 87416, tumours with no apparent myc alteration; T7,
T8, T5, T24, tumours with a rearranged c-myc locus. A control 
with carrier RNA but no sample RNA is indicated by (-). M, 
^^P-labelled markers were top, Haelll-digested and bottom, 
HinfI-digested pBR322.
Cells / tissue FeLV c-myc
rearrangement
P1/P2 ratio!
ConA / normal thymocytes - - 1.9
FEA embryo fibroblasts - - 0.8
T18 thymic LSA^ - - 4.9
86800 II II + - 3.1
T7 II II + 5' insertion 17,9
T8 II II + 5' insertion 17.0
T5 II II + 3 ‘ alteration 13.6
T24 II II + 5 * insertion -
T23 II II - - 11.8
T19 II II + - 7.7
T21 II II - - 16.2
89407 II II + - 19.6
87416 alimentary LSA + - 1.0
Table 5.2. Relative levels of c-myc PI and P2 transcripts in 
normal cells and tumours with or without 
rearrangement of the c-myc locus-
P1/P2 ratios were determined by densitcanetry of
autoradiograph bands.
LSA = lymphosarcoma.
CHAPTER SIX
ANALYSIS OF EXPRESSION OF v-myc AND c-myc GENES IN TUMOURS CONTAINING A 
myc-TRANSDUCING FeLV.
6.1 INTRODUCTION
FeLV/myc recombinant viruses have been identified in a subset of 
field cases of feline thymic lymphosarcoma (Neil et al, 1984; Levy et 
al, 1984; Mullins et al, 1984). To date, seven independent isolates 
have been identified (Table 6.1). The pathogenic properties of two 
isolates (FeLV-GT3 and -FTT) have been investigated in Glasgow (D. 
Onions et al, in press). Both viruses induced thymic tumours 12-14 
weeks after intra-peritoneal inoculation in neonatal kittens, 
indicating that FeLV/myc viruses can be causal agents of this disease. 
The disease onset was rapid compared to the usual latency of more than 
one year characteristic of inoculation of non-oncogene carrying FeLVs 
isolated from cats without tumours (D. Onions, pers. comm.). Even with 
the' highly pathogenic FeLV Rickard strain which does not appear to 
carry an oncogene, lymphosarcomas do not develop for about six months 
(Rickard et al, 1969). The FTT isolate has also been shown to be active 
in vitro transformation of primary rat fibroblasts when
co-transfected with the EJ-ras gene (D. Doggett et al, submitted).
Considerable study has been made of the structure and expression of 
the v-myc genes of well-characterised avian acute leukaemia viruses 
(Bister, 1984). However, there has been little investigation of the 
molecular biology of the v-myc genes of the more recently discovered 
FeLV/myc viruses, which represent the only examples of transduction of 
the mammalian myc gene. To begin to address this issue, the sequence of 
the three FeLV v-myc genes has been determined (Chapter 3). This 
chapter investigates another aspect: the structure and expression of
transcripts of feline v-myc genes.
When this study began, observâtions on expression of c-myc alleles 
which had been rearranged by chromosomal translocation and of normal 
c-myc alleles in Burkitt's lymphomas led to the proposal of a model of 
autoregulatory control of expression of the c-myc gene (Leder et al, 
1983; Rabbitts et al, 1984). During my study I recorded some results 
which similarly bear on control of c-myc expression. These results 
extended the earlier reports as my work was based on analysis of
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transduced v-myc genes and normal c-myc genes in feline T-cell tumours. 
6.2 RESULTS
Evidence that some feline thymic tumours contain a myc-transducinq 
FeLV was first based on Southern blot data. Further proof in three 
tumours was provided in the form of molecular clones of the FeLV/myc 
proviruses CT4, LC and FTT (Table 6.1). For tumour T3, purified virion 
RNA from cell culture supernatant has been shown to hybridise to both 
myc and exogenous FeLV U3 probes (J. Neil, pers. comm.).
6.2.1 Expression of v-myc genes
Fig.6.1 shows Northern blot analyses using a v-myc probe, of RNA 
from tumours containing FeLV/myc viruses GT3, GTll, FTT and GT17 
alongside normal cells and control tumours which do not contain an 
FeLV/myc virus. Levels of myc-hybridising RNA were dramatically 
elevated in cases with an FeLV/myc virus. It has been established that 
these highly expressed bands represent v-myc transcripts in cases 
containing viruses GT3 and FTT, by hybridisation analysis of purified 
virion RNA with a myc probe (J. Neil, pers. comm.). In tumours 
containing viruses GTll and GT17, in the absence of further evidence, 
the unusual size and high level expression of the myc-hybridising RNA 
strongly suggested that it derived from the GTll and GT17 proviruses.
6.2.2 Structures of FeLV v-myc transcripts
Northern blot analysis indicated the sizes of the largest, 
presumably genomic, v-myc RNAs produced by FeLV-GT3, GTll, GT17 and FTT 
to be approximately: GT3, 5.0 kb; GTll, 7.5 kb; GT17, 6.0 kb and FTT,
7.0 kb (Fig.6.1). In the case of FTT this agreed with the size of the 
proviral molecular clone (D. Doggett et al, submitted). For tumour 
F422, shorter autoradiographic exposure identified a 3 kb band 
corresponding to a sub-genomic v-myc RNA predicted from sequence data, 
since the FTT myc insert is downstream from the env splice acceptor 
signal (D D o g g e t t  et al, submitted). Similar analysis identified a 
single 5 kb band in RNA from tumour T3 suggesting that the GT3 v-myc 
gene is not expressed from a sub-genomic RNA. This agrees with 
immunoprécipitation studies using FeLV gag antisera, which identify a 
novel gag protein in tumour T3 which may represent a gag-myc fusion 
product (J. Neil, pers. comm.).
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6.2.3 Truncation of exon 1 in FeLV v-myc genes
All sequenced FeLV v-myc genes contain truncated exon 1 sequences
(Chapter 3). SI nuclease mapping with probe A of RNA from tumours 
containing the GT3 virus indicated that its v-myc gene included at
least 90 nucleotides upstream from the Smal site shown in Fig.6.2.
However, it did not include sequences upstream of the Sau3A site 5' to 
the P2 region as no signal was detected with probe B (Fig.6.3). The 
band was defined as viral rather than cellular since the 90 nucleotide 
band was detected in all GT3-containing tumours but not in any others.
The GTll and GT17 viral transcripts did not contain exon 1 sequences
which could be detected with probe A (Fig.6.2).
The GT3 virus contained an unusually large portion of exon 1 
compared to other studied FeLV v-myc genes. It would be of interest to 
know if this provided a novel polypeptide domain fused to the normal 
c-myc N-terminus. Confirmation of this would require cloning of the GT3 
provirus.
5.2.4 3' termini of transduced myc sequences
Fig.5.4 summarises the location of the 3' termini of the transduced 
myc sequences of four viruses. The termini of the FeLV-FTT and -LC 
isolates were respectively 12 and 99 nucleotides 3 ’ to the exon 3 stop 
codon. The myc 3' ends of the GT3 and GTll viruses appeared to be ~340 
nucleotides 3' to the exon 3 stop codon based on SI nuclease mapping 
(Fig.6.3). Until the GT3 and GTll viruses may be cloned, it cannot be 
excluded that the transduced myc sequences extend further 3' than this, 
but have acquired a mutation at this site causing an SI 
nuclease-sensitive mismatch to the probe. For the GT3 virus the band 
was defined as viral rather than cellular since it was present in all 
studied tumours containing FeLV-GT3. The GTll v-myc gene seemed to 
terminate at the same site. In all cases (FeLV-LC, -FTT, -GT3, -GTll), 
the transduced myc sequence terminates in the region between the c-myc 
exon 3 stop codon and the 5' most polyadenylation signal.
6.2.5 Lack of detectable RNA from normal c-myc alleles in tumours 
containing an FeLV/myc virus
High level v-myc expression obscured detection of RNA from the c-myc 
gene by Northern blot analysis (Fig.6.1). However, it was possible to 
investigate the presence of c-myc RNA by SI nuclease analysis as no 
known FeLV v-myc gene contains entire exon 1 or exon 3 untranslated
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sequences, facilitating distinction between c-myc and v-myc transcripts 
(see above). Tumours and tumour cell lines involving four different 
FeLV/myc viruses were analysed (Table 6.1). The tumours in which the 
viruses were identified have been shown to express high levels of v-myc 
transcripts, although this has not yet been demonstrated for all 
additional tumours induced by the GT3 and FTT viruses.
Consistently, in tumours containing an FeLV/myc virus, no c-myc RNA 
could be detected using probes A, B or C (Fig.6.2). The RNA samples had 
been shown to be intact by Northern blot analyses for expression of 
T-cell antigen receptor genes (Chapter 7). Using probe A, tumours 
containing the GT3 virus displayed an internal positive control band , 
which as discussed above represents a GT3 v-myc exon 1 sequence. As 
expected from the sequence of the FTT v-myc gene (D. Doggett et al, 
submitted), probe A did not detect any SI nuclease resistant bands in 
tumours containing this virus, as the probe did not encompass exon 1 
sequences present in FeLV-FTT.
Analysis with probe B showed that lack of detectable c-myc RNA in 
tumours containing FeLV-GT3 was not due to saturation of probe A with 
a vast excess of v-myc transcripts (Fig.6.3). Probe B should 
specifically detect c-myc PI RNA without competition from v-myc RNA, 
but again no v-myc or c-myc PI RNA was detected.
Analysis with probe C also showed that c-myc RNA could not be 
detected (Fig.6.3). Again tumours containing the GT3 virus displayed an 
internal positive control band representing transduced c-myc 3' 
untranslated sequence as discussed above. Tumour Til 'displayed a 
similar band. In tumours containing FeLV-FTT and -GT17,- no bands were 
detected. Since probe C correponded to only 12 nucleotides of the 3' 
end of the v-myc gene of FeLV-FTT, we would not expect to detect such a 
small SI nuclease-protected hybrid under the conditions used in this 
analysis. The same explanation could apply for the GT17 v-myc gene 
which has not been sequenced.
6.3 DISCUSSION
6.3.1 Expression of v-myc genes in thymic lymphosarcomas
A consistent feature of tumours in which four different FeLV/myc 
viruses have been identified is that high levels of v-myc transcripts 
are present. This suggests that v-myc transforming activity may be
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exerted through over-expression of the product, but does not discount 
the possible role of structural alterations in the myc product 
(Chapter 3). High level v-myc transcription would be driven by powerful 
FeLV LTR controls, since no studied FeLV v-myc gene retains the normal 
c-myc promoters. Tumours containing the FTT and GT3 viruses may give 
rise to transcripts from several different copies of the v-myc gene, 
since these tumours carry three to six integrated FeLV/myc 
proviruses (Neil et al, 1984; Mullins et al, 1984; D. Onions et al, 
submitted).
No known FeLV v-myc gene contains an intact c-myc exon 1 (section 
6.2.3). Therefore these may lack sequences which normally confer the 
very short half-life of the c-myc RNA (Dani et al, 1984), perhaps 
increasing v-myc RNA levels through greater stability. Deletion of exon 
1 in rearranged human and mouse c-myc genes has been reported to 
stabilise c-myc RNA (Piechaczyk et al, 1985; Rabbitts et al, 1985).
Transduced myc sequences appear to terminate upstream of the c-myc 
polyadenylation signals in all studied FeLV v-myc genes (Fig.6.4). This 
may reflect the requirement to prevent premature termination of 
transcription of the recombinant proviruses.
6.3.2 Loss of detectable transcripts from normal c-myc alleles
Eight tumours and tumour cell lines involving four different 
FeLV/myc viruses (Table 6.1) were found to lack detectable c-myc RNA 
using SI nuclease mapping probes which should detect normal c-myc RNA 
5' and 3' ends. A possibly analogous result was recorded in tumour T24 
which carries an insertion in c-myc intron 1, where RNA derived from 
the rearranged but not the normal allele could be detected (Chapters 4 
and 5). Thus, RNA could not be detected which derives from the single 
normal c-myc allele in tumour T24 or from either of the two ostensibly 
normal c-myc alleles in tumours containing a myc-transducing FeLV.
The level at which c-myc expression is being-down-regulated cannot 
be determined by these studies since SI nuclease analyses performed on 
steady-state total cellular RNA do not rule out post-transcriptional 
control. However, lack of detectable c-myc RNA using a sensitive SI 
nuclease analysis strongly suggests that transcriptional control is of 
prime importance. Further support for this view would require 
transcriptional run-off assays on isolated nuclei, or analysis of 
DNAseI hypersensitive sites at the c-myc loci.
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It has similarly been recorded that in mouse lymphoid cells and
fibroblasts infected with, and in tumours induced by, recombinant MuLVs
which express an avian v-myc construct, c-myc RNA was not detected 
(Rapp et al, 1985; Morse et al, 1986). Likewise it has been reported
that in human and mouse B-cell lymphomas with a translocated c-myc
gene, the rearranged allele is expressed but the normal allele is not 
or is expressed at very reduced levels (ar-Rushdi et al, 1983; Bernard 
et al, 1983; Rabbitts et al, 1984; Taub et al, 1984a; Fahrlander et al, 
1985b). Also, in tumours in transgenic mice which carry and express a 
c-myc construct, and in tumours derived from fibroblasts which carry a 
c-myc construct, normal endogenous c-myc RNA could not be detected 
(Adams et al, 1985; Keath et al, 1984).
In general, expression of the c-myc gene occurs in growing cells, 
being elevated upon growth stimulation and reduced with growth 
inhibition (Kelly et al, 1983; Reed et al, 1985; Re it sma et al, 1983; 
Lachman & Skoulchi, 1984). Hence, it is intriguing that actively 
growing feline T lymphocytic tumour cells which carury an FeLV/myc virus 
contain no detectable RNA from the endogenous c-myc gene. The 
consistent association between the presence of any one of four 
different FeLV v-myc genes and the lack of detectable c-myc RNA 
suggests that down-régulâtion is related to expression of the v-myc 
genes perhaps in accord with the proposal that expression of the c-myc 
gene is under negative feedback control mediated directly or indirectly 
by the myc product (Leder et al, 1983; Rabbitts et al, 1984). It would 
be possible to test this idea directly in the feline system by 
manipulation of the myc coding sequence in cloned FeLV/myc viruses to 
investigate the role of the myc product in this phenomenon. As 
virtually nothing is known of the normal function of the myc product, 
it can only be speculated that loss of normal c-myc expression 
directly contributes to transformation or instead is only coincidental 
to the transformation process mediated by v-myc genes.
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FeLV/myc
virus
involved
Tumour
case
Primary tumour 
(P ) or tumour 
cell line (L)
Tumour of origin 
of virus or 
tumour induced 
by virus
Proviral
molecular
clone
Ref
FeLV-CT4 84793 P origin + 1
FeLV-Cl 84929 P origin - 1
FeLC-LC 1110 P origin + 2
FeLV-GTll Til P origin - 1
FeLV-GT17 T17 P origin + 5
FeLV-GT3 T3 L origin - 1
fl GT3-C4 P induced - 3
II GT3-C8 L induced - 3
FeLV-FTT F422 L origin + 4
II F422-1 P induced * 3
It F422-3 P induced * 3
Table 6.1. Characteristics of thymic tumours which contain 
a myc-transducing FeLV.
* Although a molecular clone of FeLV-FTT exists, virus 
stocks from the original tumour cell line F422 were used to 
induce tumours F422-1 and F422-3 (ref. 4).
Refs. 1, Neil et al, 1984; 2, Levy et al, 1984; 3, D. Onions et 
al, in press; 4, Mullins et al, 1984; 5, bacteriophage/\ clone, 
R. Fulton, pers. comm..
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Fig.5.1. Northern blot analyses using a v-myc probe of RNA 
from tumours.
RNAs were from tumours containing an FeLV/myc virus (T3, 
F422, Til, T17), a c-myc rearrangement (T7) or no myc 
alteration (FL74), and normal embryo fibroblasts (FEA) and 
ConA activated normal thymocytes (Act. thym.).
All lanes contained 20pg of total cellular RNA except for 
lanes T3 and F422 in the right panel which contained 4pg 
samples. All autradiographs were exposed to film overnight, 
except for the right panel which was exposed for 6h. The 
probe was derived from the pCT4 clone (Fig.4.1).
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Fig.5.2. SI nuclease analysis of RNA from tumours containing 
an FeLV/myc virus.
Top: The origins of probes A, B and C used in the studies 
shown in Figs.6.2 and 6.3 were the same as described in 
Fig.5.1. Restriction enzyme abbreviations; B2, Bglll; H, 
Hindlll; S, Sau3A; Sm, Smal; X, XhoII.
Bottom: Results of analysis using probe A of tumours 
containing FeLV/myc viruses and of tumour 86800 with no 
detectable myc alteration. (-) represents a control with only 
carrier rRNA and no sample RNA.
M, Haelll-digested 0X174, ^^P-labelled markers.
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F i g . 6 . 3 SI nuclease analysis using probes B (top) and C 
(bottom) of RNA from tumours containing an FeLV/myc
virus-
All samples and marker lanes are as described in Fig.6.2 
except tumour T19 which has no detectable myc alteration. Th« 
right hand marker lane of panel C contained HinfI-dlgested 
pBR322, labelled with
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TCATATCTBAACTTGTTTCAAATGCAT6GTCAAQT6CAACCTCACAACCTTGGCTGGGTCTTAGGATTSA
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ATACAAGAATTCCATGTATTATAAACCATAATTTTTTTTATTTAAGTACATTTTCCTTTTTAAAGTTGAT
TTTTTCTATTGTTTTTAGAAAflÂÂTAAAhTACGTGGCAAATATATAATTGAGCCAAATCTTAAGTTGTGA
GTGTTTTGTTTTTCTTGCCTTTTTTTTCTATTTTCTTTTCATCAATTCCAATTAACAGAATTTGGCCCTC
Fig.6.4. Location of the 3 ’ termini of transduced myc 
sequences in FeLV/myc viruses.
Consensus polyadenylation signals are shown in boxes, and 
the 3' v-myc termini are indicated by vertical arrows above 
the sequence. The FeLV-FTT and LC 3' termini were based on 
sequence data (Braun et al, 1985; D. Doggett et al, 
submitted) and those of FeLV-GT3 and GT17 on SI nuclease
analyses (Fig.6.3).
CHAPTER SEVEN
EXPRESSION OF T CELL ANTIGEN RECEPTOR GENES
7.1 INTRODUCTION
Most of the tumours available for study in the Glasgow series were 
field case thymic lymphosarcomas, although some other haemopoietic 
tumour types were represented. Although on pathological examination 
the tumours were thymic in origin, it has only recently become 
possible, following the cloning of genes for various T-cell marker 
molecules, to characterise their phenotype at a finer level. This study 
approached several issues concerning lymphosarcoma development. For 
example, expression of T-cell markers would provide strong evidence
that the tumours were of T-cell origin. It would also be interesting to
ask if the phenotype of the tumours in which the GT3 and FTT viruses
were identified was reproduced in tumours induced by these viruses.
This would help define the transforming spectrum of FeLV/myc viruses.
The differentiation stages of human and murine T-cells have been 
characterised with series of monoclonal antibodies (Reinherz et al, 
1980). More recently, cDNA clones have been isolated for components of 
the T-cell antigen receptor (TCR) and various T-cell differentiation 
markers which define T-cell subsets (Collins & Owen, 1985; Parnes, 
1986). Use of these clones as hybridisation probes has facilitated 
analysis of T-cell developmental pathways. Thus, it is apparent that 
prior to expression, the ct- and |3-chain genes of the TCR rearrange in 
a similar fashion to immunoglobulin genes in B-cell development (Hood 
et al, 1985). Expression of TCR genes appears to occur relatively late 
in T-cell development, with that of the p-chain preceding that of the 
a-chain (Collins et al, 1985; Furley et al, 1986).
I undertook initial characterisation of the series of feline tumours 
by Northern blot analysis using probes from cDNA clones of the human 
TCR a- and (3-chain genes (Collins et al, 1985).
7.2 RESULTS
7.2.1 Detection of TCR a- and (3-chain transcripts in thymic tumours
Northern blot analysis with the TCR CL-chain probe detected a band 
of 1.6 kb and the |3-chain probe detected a band of 1.4-1.6 kb in RNA 
from thymic tumours and norma.( thymocytes (Fig.7.1). These sizes are
60
similar to a- and p-chain RNAs detected in human and mouse T-cells 
(Yoshikai et al, 1984; Collins & Owen, 1985). The diffuse P-chain band 
could in some cases be resolved into two bands (Fig.7.2, lane T3). By 
analogy with human T-cells, the shorter p-chain RNA probably results 
from incomplete rearrangement of one of the TCR P-chain alleles. In 
some cases a fainter 4.5 kb band was detected which may represent a 
precursor of the mature P-chain RNA. The specificity of the probes was 
demonstrated in that thymic tumours and normal thymocytes displayed 
strong cc- and P-chain bands, whereas only a faint background smear was 
detected in embryonic fibroblasts and in normal kidney and spleen 
tissues. Tumour FL74 did not contain detectable P-chain RNA but 
appeared to express low levels of a-chain RNA.
7.2.2 Expression of TCR a -  and P-chain transcripts in tumours 
containing FeLV/myc viruses.
Fig.7.2 shows that tumours in which FeLV/myc viruses were 
discovered, and additional tumours induced by FeLV-GT3 and FTT, 
expressed both a- and P-chain RNAs. Tumour T17 in which FeLV-GT17 was 
identified, expressed a normal a-chain transcript but displayed gross 
elevation of an abnormally large P-chain transcript.
7.3 DISCUSSION
7.3.1 Expression of TCR a -  and P-chain RNAs in thymic tumours
Several thymic tumours studied produce TCR a -  and P-chain. RNAs. Some 
tumours have also been shown to contain rearranged TCR P-chain genes 
(J. Neil and R. McFarlane, pers. comm.). Rearrangement normally 
precedes expression in human and murine T-cells (Collins & Owen, 1985). 
Tumours expressing a -  and P-chain RNAs would be of relatively mature 
phenotype by analogy with human T-cells where TCR expression occurs 
late in differentiation (Collins et al, 1985; Royer et al, 1985).
However, not all cases showed rearrangement of the P-chain gene 
indicating some phenotypic heterogeneity. Interestingly, the leiikaemic 
FL74 line seemed to express only a-chain RNA suggesting that it may 
represent a less mature T-cell tumour. A study of several AKR mouse 
thymic lymphoma lines showed that many expressed normal a -  but not 
p-chain RNA, and may represent a distinct T-cell subset (Owen et al, 
1986).
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7.3.2 The phenotype of tumours induced by FeLV/myc viruses
Avian myc-transducing viruses induce a wide spectrum of tumours 
including various leukaemias and carcinomas in chickens (Hayman, 1983). 
Also, recombinant MuLVs carrying an avian myc construct induce a range 
of haemopoietic and epithelial tumours in NFS/N mice (Morse et al, 
1986), although another MuLV/avian v-myc construct has been found to 
induce lymphoid leukaemias and T-cell lymphomas in NIH Swiss mice 
(Brightman et al, 1986). In contrast, tumours induced by FeLV/myc 
viruses have been found consistently to be thymic lymphosarcomas, 
expressing TCR a- and p-chain RNA. Similarly, feline thymic tumours 
with a rearranged c-myc gene which were studied also express TCR el­
and p-chain genes (cases T7, T8, T5).
The mono- or oligoclonal nature of the tumours induced by FeLV/myc 
viruses suggests that not all cells which are infected become 
transformed, but only those rare cells which acquire a secondary 
transforming event. The nature of such additional events is not clear 
at present but the restricted phenotype of the thymic tumours raises 
intriguing possibilities. This restriction may reflect a requirement 
for the molecular events associated with rearrangement and expression 
of the TCR genes, or for the expression of a functional antigen 
receptor. Thus, aberrant recombination events could activate cellular 
oncogenes, as may be the case with abnormally joined c-myc and TCR 
a-chain genes in some human T-cell leukaemias (Erikson et al, 1986; 
Shima et al, 1986).
It is also possible that T-cells which express functional antigen 
receptors and hence are responsive to antigenic growth stimuli, are 
most susceptible to transformation by FeLV/myc viruses or rearranged 
c—myc genes. This proposal could be in accord with the model of McGrath 
et al (1980) for murine T-cell lymphomagenesis. This suggests that 
MuLV-infacted T-cells are subject to repetitive mitogenic stimulation 
of their antigen receptors by viral env products. Perhaps feline 
T-cells which carry an altered myc gene and which express a functional 
TCR specific for viral antigens may be selected in tumour development.
7.3.3 Identification of a TCR P-chain gene transduced by FeLV
This study uncovered one apparently exceptional case of involvement 
of TCR genes in feline thymic lymphosarcoma. In tumour T17 the highly 
expressed, abnormally large chain RNA was reminiscent of the pattern
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of expression of a transduced myc gene from an FeLV/myc provirus 
(Chapter 6). Southern blot analysis with the P-chain probe supported 
the possibility that this tumour contained an FeLV provirus which had 
transduced a TCR P-chain gene and this has since been confirmed by 
isolating a clone of the provirus (R. Fulton, D. Forrest, R. McFarlane, 
D. Onions and J. Neil, in press). Therefore this tumour contained two 
independently transduced cellular genes: v-myc and v-tcr (T-cell
receptor P-chain) in different FeLV proviruses. Although pathogenesis 
studies have still to be performed with these viruses, it is likely 
that both v-myc and v-tcr genes play leukaemogenic roles. It could be 
speculated that the v-tcr product provides a constitutive mitogenic 
signal from the cell membrane and the v-myc product cooperates in 
transformation at a later stage in the mitogenic signalling pathway in 
the nucleus.
—
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Fig.7.1. Northern blot analysis using TCR a- and p-chain 
probes of RNA from tumours and normal cells.
RNA samples were: tumours with a rearranged c-myc gene, T7, 
T8, T5; tumours with no detectable myc alteration, FL74, T14, 
86800; normal cells, mitogen activated normal thymocytes,
ANT, and embryo fibroblasts, FEA. After hybridisation, washes 
were performed in 2X SSC at 60°C (Chapter 2). Autoradiographs 
involved exposure overnight for P-chain results and over two 
nights for a-chain results.
Size markers were Hindlll-digested /\DNA labelled with
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Fig.7.2. Northern blot analysis using TCR a- and (3-chain 
probes of RNA from tumours containing an FeLV/myc 
virus.
RNA samples were from tumours described in Table 6.1, from 
normal spleen and kidney tissue and FEA embryo fibroblasts. 
Filter washing and autoradiography conditions and size 
markers were as described in Fig.7.2.
CHAPTER EIGHT
GENERAL SUMMARY AND DISCUSSION
In this study I have examined in detail the involvement of the myc 
gene in some feline lymphosarcomas, and have considered other genes 
which may play a part in this disease.
8.1 THE myc GENE IN FELINE LEUKAEMIAS
Unlike the situation in the murine and avian species where certain 
types of tumour are generally associated with one mode of retroviral 
activation of the myc gene, feline thymic lymphosarcomas show a variety 
of mechanisms. This diversity could result from study of 
naturally-occurring and experimental tumours in the cat whereas study 
of only experimentally-induced tumours in other species may cause bias 
in the findings. Experimental induction of tumours with retroviruses is 
known to be influenced by various factors including the host age and 
genetic status, the strain of virus, and the dose and route of virus 
inoculation (Teich et al, 1985). Thus, it is possible that experimental 
studies select for specific oncogenic mechanisms.
8.1.1 The feline c-myc gene (Chapter 3)
The feline c-myc gene is highly related to that of the other 
mammalian species (human, mouse), especially to that of man, but is 
less well related to that of the chicken. Homology is greatest across 
the coding exons 2 and 3, but is also considerable in the apparently 
non-coding exon 1 region of the the mammalian (feline, human, mouse) 
genes. The sequence of the three mammalian c-myc genes in each case 
reveals a putative dual promoter structure. The similarities in the 
mammalian genes were supported by SI nuclease analyses showing that 
normal feline cells contain two major c-myc RNAs (PI and P2) mapping to 
the two promoter-like elements, which possess a common 3 end 
corresponding to the most 3' of two possible . polyadenylation signals 
(Chapter 5).
8.1.1 Transduction
Transduction of myc by FeLV is common in field case thymic tumours 
with seven independent isolates reported at present (Chapter 6). Each 
FeLV/myc virus is thought to have arisen ^  novo in the tumour in which 
it has been identified, since experimental evidence indicates that they 
are not transmitted horizontally (D. Onions et al, in press). This
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proposal is also supported by sequence and SI nuclease analysis of 
FeLV-myc recombination points, which have been found to differ between 
isolates, with an exception being a possible common 3 ’, though not 5', 
terminus in the v-myc gene of the GT3 and GTll viruses (Chapter 6).
Study of two FeLV/myc viruses shows them to induce thymic tumours 
which express TCR a and (3-chain RNAs (Chapter 7; D. Onions et al, in 
press). This narrow oncogenic spectrum could be due to properties of 
FeLV and/or the myc gene. The enhanced transcriptional activity of FeLV 
LTRs in lymphoid cells (J. Casey, pers. comm.) may be an important 
factor and may account for the high levels of v-myc RNA present in 
tumours containing FeLV/myc viruses (Chapter 5).
Transduced myc genes in every case incorporate both coding exons 2 
and 3 suggesting that an intact myc product without N or C-terminal 
truncation is necessary for oncogenic function (Chapter 3). In FeLV-CT4 
and -FTT the predicted v-myc gene may not be fused to any viral 
structural gene product, but the LC isolate apparently codes for a 
gag-myc fusion product. The v-myc sequences of FeLV-CT4 and -FTT show 
few coding changes relative to the normal c-myc gene, and that of 
FeLV-LC shows none. However, the possible oncogenic role of structural 
alterations to the myc product remains to be systematically 
investigated, and this could be a useful extension to the studies 
described here.
8.1.2 Rearrangements of the c-myc locus
In addition to transduction, various forms of rearrangement of the 
c-myc locus have been found in thymic tumours (Chapter 4). One field 
and one experimental case in the Glasgow series of tumours and 8/11 
experimental tumours studied by J. Mullins (pers. comm.) involve FeLV 
proviruses in the "enhancer insertion" mode upstream of the c-myc gene. 
Presumably some form of selection operates in these experimental 
tumours, which had all been induced by the highly pathogenic Rickard 
strain of FeLV, to favour this mode of myc alteration. Similarly, 
enhancer insertions are common in murine thymic lymphomas induced by 
highly leukaemogenic MuLVs (Selten et al, 1984). This may reflect 
possession of LTR transcriptional controls which are especially active 
in T-cells (Celander & Haseltine, 1984).
In contrast, tumour T24 appears to carry a truncated provirus in 
intron 1 in the "promoter insertion" mode, and may represent a
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structural intermediate in the pathway to myc transduction by FeLV. The 
possible presence of a new FeLV/myc virus could be tested further for 
example, by investigating tumour formation following inoculation with 
cell-free extract from tumour T24.
Tumour T5 is another unusual case, since it seems to contain a
single normal c-myc allele and two 3' rearranged alleles, which do not
appear to involve FeLV sequences. It is intriguing to speculate that 
chromosomal rearrangements involving the c-myc and TCR gene loci may 
have occurred, as recently reported in a few human T-cell leukaemias 
(Shima et al, 1986; Erikson et al, 1986).
8.1.3 Expression of the c-myc gene in feline tumours
Analysis of RNA from the tumour series revealed different modes of 
c-myc expression. Rearrangements at the c-myc locus do not result in 
obvious abnormalities in transcription, since levels of c-myc 
transcripts are not grossly elevated, and RNA with altered structure is 
produced in only one case (tumour T24) (Chapter 5). However, the view 
that upstream FeLV insertions in tumours T7 and T8 contribute to c-myc 
transcriptional deregulation is supported by finding that these tumours 
contain a high ratio of PI to P2 c-myc transcripts. This could result 
from enhancers in the FeLV LTRs preferentially activating the proximal 
(PI) promoter. But other factors must also be involved as some tumours 
with no apparent c-myc alteration display an equally high P1/P2 ratio. 
More conclusive interpretation of these studies awaits clearer 
definition of the normal pattern of c-myc transcription and of the cis 
and trans-acting factors which control its expression.
Evidence for the complexity of control of c-myc expression was 
uncovered in tumours expressing any of four different FeLV v-myc 
genes, where RNA could not be detected which derived from the 
ostensibly normal c-myc alleles in these tumours (Chapter 6). Similarly 
in tumour T24, RNA was detected which derived from the rearranged c-myc 
allele, but not the normal allele. Although it was not possible to 
distinguish between transcripts from the normal and rearranged c-myc 
alleles in tumours T7 and T8, precedent from other species suggests 
that the RNA may again derive from the rearranged alleles (ar-Rushdi et 
al, 1983; Bernard et al, 1983). Since this c-myc down-regulation was 
found consistently with different FeLV/myc viruses this may support 
models where c-myc expression is under negative autoregulatory control
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(Leder et al, 1983), although the role of the myc product in this 
phenomenon remains to be examined. However, other explanations are not 
excluded; for example, c-myc normally may be down-regulated at a 
certain maturation stage in the target cells for transformation by 
FeLV/myc viruses.
My data for feline tumours, with those recorded for human and murine 
tumours, also suggest that loss of expression of normal c-myc alleles 
may prove to be a useful indicator of the presence of an oncogenically 
active myc gene, whether this is a rearranged c-myc or transduced v-myc 
sequence.
8.2 OTHER CELLULAR GENES INVOLVED IN FELINE LEUKAEMIAS
As the myc gene is only implicated in a subset of thymic 
lymphosarcomas, other genes may be involved in other cases. By analogy 
with MuLV-induced thymic lymphomas these genes may include the pim-1, 
tck or Mlvi loci (Cuypers et al, 1984; Voronova & Sefton, 1986; 
Tsichlis et al, 1983). An early part of my work involved screening the 
available tumour series for additional genetic rearrangements. This 
showed thymic tumour 84904 to carry a rearranged pim-1 restriction 
fragment which was also amplified <five-fold relative to the normal 
pim-1 fragment in the same tumour (Fig.8.1). It was not feasible to 
investigate linkage with FeLV sequences, as this tumour contained a 
very high copy number of proviruses, and the rearranged fragment would 
need to be cloned for further study.
A novel candidate gene for oncogenic function was a TCR (3-chain gene 
transduced by FeLV in tumour T17 (Chapter 7). A molecular clone of this 
provirus is now available for functional analysis (R. Fulton et al, in 
press). Since the TCR normally is involved in transmitting mitogenic 
signals into the cell as well as in antigenic recognition (Smith, 1985) 
it is conceivable that the viral TCR (v-tcr) gene contributes to 
abnormal cell growth.
8.3 MULTISTAGE LEUKAEMOGENESIS
Several observations indicate that feline thymic lymphosarcomas 
arise by a series of events, consistent with theories of multistep 
oncogenesis (Klein & Klein, 1985). First, FeLV/myc viruses induce mono 
or oligoclonal tumours. If it is presumed that many cells may be 
infected by these viruses, this may be evidence that the cells which 
form tumours are selected by additional events. Recombinant MuLV/myc
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constructs have also been found to induce clonal tumours in mice (Morse 
et al, 1986; Brightman et al, 1986). Secondly, FeLV/myc viruses have 
not been found to transform feline thymocytes, embryo fibroblasts or 
bone marrow cells in culture (D. Onions, pers. comm.) again suggesting 
the need for secondary events. This is supported by finding that 
co-transfection of an FeLV/myc virus and an EJ-ras gene transforms rat 
embryo cells, which is not achieved with either clone by itself (D. 
Doggett et al, submitted). Thirdly, experimental induction of clonal 
thymic tumours by FeLVs which do not carry an oncogene is generally a 
slow process (>1 year; Mackey et al, 1973; D. Onions, pers. comm.). The 
long latency may be explained as the time required for the occurrence 
of several oncogenic events in the same cell necessary for it to form a 
tumour.
A possible line of future investigation concerns the nature of such 
additional oncogenic events. One possibility is direct involvement of 
more than one oncogene. This may be the case in tumour T17 which in 
addition to an FeLV/ter virus is known to contain an FeLV/myc virus 
(Chapter 7). This is the first report of two independent transductions 
of genes with oncogenic potential in the same tumour.
However, there are reports on tumours in other species where two
cellular genes with oncogenic potential may sustain proviral insertions 
(Selten et al, 1984; Tsichlis et al, 1985; Peters et al, 1986). 
Analysis of murine thymic lymphomas suggested that emergence of a 
dominant tumour cell clone may be associated with additional proviral 
insertions, perhaps identifying genes for tumour progression (Cuypers 
et al, 1986). A variation on this theme may be feline tumour T5 which 
contains a c-myc rearrangement apparently not linked to FeLV sequences, 
and a low copy number of integrated FeLV elements (Chapter 4).
Investigation of the cellular loci at which the FeLV sequences are
inserted may identify genes with oncogenic potential which have 
cooperated with the rearranged c-myc gene in the genesis of this 
tumour.
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Fig.8.1. Southern blot analysis of tumours to screen 
for rearrangement of the pim-1 locus.
Xbal-digested DNAs were hybridised with a mouse Pim-1 
plasmid insert (Table 2.1). Hybridisation was performed in 
40% formamide at 35°C, and washes were in 2X SSC / 0.5% SDS 
at 39°C (Chapter 2).
No control normal tissue was available from the cat with 
tumour 84904. Controls where available were DNAs from normal 
kidney of the cats with tumours.
Lanes from left to right; tumours 84904, 84793, tumour T5 
and control, tumour TIO and control, tumour 86503 and 
control, tumour 89407 and control.
Size markers were Hindlll-digested )\DNA, labelled with 32p
REFERENCES
Adams, J. M. (1985) Nature 315, 542-543.
Adams, J. M., Harris, A. W., Pinckert, C. A., Corcoran, L. M. ,
Alexander, W. S., Cory, S., Palmiter, R. D. & Brinster, R. L. (1985) 
Nature 3^, 533-538.
Alitalo, K., Schwab, M., Lin, C. C., Varmus, H. E. & Bishop, J. M.
(1983) Proc. Nat. Acad. Soi. USA 80, 1707-1711.
Anderson, L. J., Jarrett, W. F. H., Jarrett, 0. & Laird, H. M. (1971)
J. Nat. Cancer Inst. 47, 807-817.
Ashley, D. J. B. (1969) Br. J. Cancer 23, 313-328.
ar-Rushdi, A., Nishikura, K., Erikson, J., Watt, R., Rovera, G. &
Croce, C. M. (1983) Science 222, 390-393.
Barbacid, M. (1986) Trends Genet. 2, 188-192.
Battey, J., Moulding C., Taub, R., Murphy, W., Stewart, T., Potter, H., 
Lenoir, G. & Leder, P. (1983) Cell 84, 779-787.
Bentley, D. L. & Groudine, M. (1986a) Nature 321, 702-706.
Bentley, D. L. & Groudine, M. (1986b) Mol. Cell. Biol. 6, 3481-3489.
Benton, W. D. & Davis, R. W. (1977) Science ]^, 180-182.
Bernard, 0., Cory, S., Gerondakis, S., Webb E. & Adams, J. M. (1983) 
EMBO. J. 2, 2375-2383.
Besmer, P. (1983) Curr. Top. Microbiol. Immunol. 107, 1-27.
69
Besmer, P., Murphy, J. E., George P. C., Qiu, F-H., Bergold, P. J. , 
Lederman, L., Snyder, H. W., Brodeur, D., Zuckerman, E. E. &
Hardy W. D. (1986a) Nature 3 ^, 415-421.
Besmer, P., Lader, E., George, P. C., Bergold, P. J., Qiu, F-H., 
Zuckerman, E. E. & Hardy, W. D. ( 1986b)^^, 194-203.
3. V i r » i  .
Bishop, J. M. (1983) Ann. Rev. Biochem. 52, 301-354.
Bishop, J. M. (1985) Cell 42, 23-38.
Bishop, J. M. & Varmus, H. E. (1985) pp. 249-356, in R. Weiss,
N. Teich, H. Varmus & J. Coffin (eds.), RNA Tumour Viruses, 2nd
edition, supplement. Cold Spring Harbor Laboratory , New York.
Bister, K. (1984) pp. 38-63, in J. M. Goldman & O. Jarrett (eds-). 
Mechanisms of Viral Leukaemogenesis, Churchill Livingstone, 
Edinburgh.
Braun, M. J., Deininger, P. L. & Casey, J. W. (1985) J. Virol. 
177-183.
Breathnach, R. & Chambon, P. (1981) Ann. Rev. Biochem- M ,  349-383.
Brightman, B. K., Pattengale, P. K. & Fan, H. (1986) J. Virol.
60, 63-81.
Brown, A. M. C. , Wildin, R. S., Prendergast, T. J. & Varmus H- É. 
(1986) Cell 1001-1009.
Bunte, T., Donner, P., Pfaff, E., Reis, B., Greiser-Wilke, I-, 
Schaller, H. & Moelling, K. (1984) ElffiO. J. 3, 1919-1924.
Campisi, J., Gray, H. E., Pardee, A- B., Dean, M. & Sonenshein, G. E.
(1984) Cell 36, 241-247.
70
Care, A., Cianetti, L., Giampaolo, A., Sposi, N. M., Zappavigna, V., 
Mavilio, F., Alimena, G., Amadori, S., Mandelli, F. & Peschle, C. 
(1986) EMBO. J. 5, 905-911.
Casey, J. W., Roach, A., Mullins, J. I., Burck, K. B., Nicolson, M. 0., 
Gardner, M. B. & Davidson, N. (1981) Proc. Nat. Acad. Sci. USA 
U ,  7778-7782.
Celander, D. & Haseltine, W. A. (1984) Nature 312, 159-162.
Chen, S. J., Holbrook, N. J., Mitchell, K. F., Vallone, C. A.,
Greengard, J. S., Crabtree, G. R. & Lin, Y. (1985) Proc. Nat. Acad. 
Sci. USA 82, 7284-7288.
Chen, I. S., Wachsman, W., Rosenblatt, J. D. & Cann, A. J. (1986)
Cancer Surveys 5, 329-342.
Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J. & Rutter, W. J. 
(1979) Biochem. 18, 5294-5299.
Cohen, J. C., Shank, P. R., Morris, V. L., Cardiff, R. & Varmus, H. E.
(1979) Cell 16, 333-345.
Cohen, J. B. , Unger, J., Rechavi, G., Canaani, E. & Givol, D. (1983) 
Nature 306, 797-799.
Collins, S. & Groudine, M. (1982) Nature 298, 679-681.
Collins, M. K. L. & Owen, M. J. (1985) Biochem. J. 230, 281-291.
Collins, Tanigawa, G., Kissonerghis, A-M., Ritter, M., Price, K. M., 
Tonegawa, S. & Owen, M. J. (1985) Proc. Nat. Acad. Sci. USA 
82, 4503-4507.
Corcoran, L. M., Adams, J. M., Dunn, A. R. & Cory, S. (1984) Cell 
37, 113-122.
71
Cory, S., Graham, M., Webb, E., Corcoran, L. & Adams J. M. (1985)
EMBO. J. 4, 675-681.
Crittenden, L. B. & Kung, H-J. (1984) pp. 64-88, in J. M. Goldman &
0. Jarrett (eds.). Mechanisms of Viral Leukaemogenesis, Churchill 
Livingstone, Edinburgh.
Cuypers, H. T., Selten, G., Quint, W., Zijlstra, M., Maandag, E. R., 
Boelens, W., van Wezenbeek, P., Melief, C. & Berns, A. (1984) Cell 
37, 141-150.
Cuypers, H. T. M., Selten, G. C., Zijlstra, M., De Goede, R. E.,
Melief, C. J. & Berns, A. (1986) J. Virol. 60, 230-241.
Dalla-Favera, R., Gelmann, E. P., Martinotti, S., Franchini, G.,
Papas, T. S., Gallo, R. C. & Wong-Staal, F. (1982) Proc. Nat. Acad, 
Sci. USA 79, 6497-6501.
Dani, C., Blanchard, J. M., Piechaczyk, M., Sabouty, S. E., Marty, L. & 
Jeanteur, P. (1984) Proc. Nat. Acad. Sci. USA 81, 7046-7050.
DePinho, R. A., Legouy, E., Feldman, L. B., Kohll, N. E,,
Yancopoulos, G. D. & Alt, F. W. (1986) Proc. Nat. Acad. Sci. USA 
83, 1827-1831.
Dickson, C., Smith, R., Brookes, S. & Peters, G. (1984) Cell 
37, 529-536.
Drabkin, H. A., Bradley, C., Hart, I., Bleskan, J., Li, F. P. & 
Patterson, D. (1985) Proc. Nat. Acad. Sci. USA 82, 6980-6984.
Dynan, W. S. & Tijan, R. (1985) Nature 316, 774-778.
Eisemnan, R. N. & Thompson, C. B. (1986) Cancer Surveys 5, 309-327.
Enrietto, P. J., Payne, L. N. & Hayman, M. J. (1983) Cell 35, 369-379.
72
Enrietto, P. J. & Wyke, J. A. (1983) Adv. Cancer Res. 269-314.
Erikson, J., ar-Rushdi, A., Drwinga, H. L., Nowell, P. C. &
Croce, C. M. (1983) Proc. Nat. Acad. Sci. USA 80, 820-824.
Erikson, J. , Finger, L., Sun, L., ar-Rushdi, A., Nishikura, K.,
Minowada, J., Finan, J., Emanuel, B. S., Nowell, P. C. &
Croce, C. M. (1986) Science 232, 884-886.
Fahrlander, P. D., Sumegi, J., Yang, J-Q., Wiener, F., Marcu, K. B & 
Klein, G. (1985a) Proc. Nat. Acad. Sci. USA 82, 3746-3750.
Fahr lander, P. D., Piechaczyk, M. & Marcu, K. B. (1985b) EMBO. J.
4, 3195-3202.
Favoloro, J., Treisman, R. & Kamen, R. (1980) Meths. Enzymol.
65, 718-749.
Ficht, T. A., Chang, L-J. & Stoltzfus, C. M. (1984) Proc. Nat. Acad. 
Sci. USA 81, 362-366.
Fung, Y-K. T., Fadly, A. M., Crittenden, L. B. & Kung, H-J. (1981)
Proc. Nat. Acad. Sci. USA 78, 3418-3422.
Fung, Y-K. T., Fadly, A. M., Crittenden, L. B. & Kung, H-J. (1982)
Virol. 119, 411-421.
Fung, Y-K. T., Lewis, W. G., Crittenden, L. B. & Kung, H-J. (1983) 
Cell 33, 357-368.
Furley, A. J. , Mizutani, S., Weilbaecher, K., Dhaliwal, H. S.,
Ford, A. M., Chan, L. C., Molgaard, H. V., Toyonaga, B., Mak, T., 
van den Elsen, P., Gold, D., Terhorst, C. S Greaves, M. (1986) 
Cell 46, 75-87.
Gazin, C., de Dinechin, S. D., Hampe, A., Masson, J-M., Martin, P., 
Stehelin, D. & Galibert, F. (1984) EMBO. J. 3, 383-387.
73
Gazin, C., Rigolet, M., Briand, J. P., Van Regenmortel, M. H. V. & 
Galibert, F. (1986) EMBO. J. 5, 2241-2250.
Gonda, T. J., Sheiness, D. & Bishop, J. M. (1982) Mol. Cell. Biol.
2, 617-624.
Graham, M. , Adams, J. M. & Cory, S. (1985) Nature 3JA, 740-743
Greenberg, R., Hawley, R. & Marcu, K. B. (1985) Mol. Cell. Biol.
5, 3625-3628.
Greene, W. C., Leonard, W. J., Wano, Y., Svetlik, P. B., Peffer, N. J., 
Sodroski, J. G., Rosen, C. A., Goh, W. C. & Haseltine, W. A. (1986) 
Science 232, 877-880.
Hall, L. M. C, (1981) Ph.D. Thesis, Glasgow University.
Hanahan, D ., (1983) J. Mol. Biol. 166, 557-580.
Hann, S. R., Thompson, C. B. & Eisenman, R. N. (1985) Nature 
314, 366-369.
Hardy, W. D., Old, L. J., Hess, P. W., Essex, M. & Cotter, S. (1973) 
Nature 244, 266-269.
Hayflick, J., Seeburg, P. H., Ohlsson, R., Pfeiffer-Ohlsson, S.,
Watson, D., Papas, T. & Duesberg, P. H. (1985) Proc. Nat. Acad.
Sci. USA 82, 2718-2722.
Hayman, M. (1983) Curr. Top. Microbiol. Immunol. 103, 109-125.
Hayward, W. S., Neel. B. G. & Astrin, S. M. (1981) Nature 290, 475-479.
Heaney, M. L., Pierce, J. & Parsons, J. T. (1986) J. Virol.
60, 167-176.
74
Heldin, C. H. & Westerraark, B. (1984) Cell 37, 9-20.
Hollis, G. F., Mitchell, K. F., Battey, J., Potter, H., Taub, R., 
Lenoir, G. M. & Leder, P. (1984) Nature 307, 752-755.
Hood, L., Kroneberg, M. & Hunkapiller, T. (1985) Cell 40, 225-229.
Huang, C-C., Hay, N. & Bishop, J. M. (1985) Cell 935-940.
Huebner, R. & Todaro, G. (1969) Proc. Nat. Acad. Sci. USA 
64, 1087-1094.
Ihle, J. N. & Lee, J. C. (1982) Curr. Top. Microbiol. Immunol.
98, 85-101.
Jakobovits, E. B., Majors, J. E. & Varmus, H. E. (1984) Cell 
757-765.
Jarrett, 0. (1984) pp. 135-154, in J. M. Goldman & 0. Jarrett (eds.). 
Mechanisms of Viral Leukaemogenesis, Churchill Livingstone, 
Edinburgh.
Jarrett, 0., Laird, H. M. &Hay, D. (1973) J. Gen. Virol. 20., 169-175.
Jarrett, 0., Hardy, W. D., Golder, M. & Hay, D. (1978) Int. J. Cancer 
21, 334-337.
Jarrett, 0., Golder, M. C. & Stewart, M. F. (1982) Vet. Record 
110, 225-228.
Jarrett, W. F. H., Martin, W. B., Crighton, G. W., Dalton, R. G. & 
Stewart, M. F. (1964) Nature 202, 566-568.
Kaczmarek, L. , Hyland, J. K., Watt, R., Rosenberg, M. & Baserga, R. 
(1985) Science 228, 1317-1315.
75
Katzir, N., Rechavi, G., Cohen, J. B., Unger, T., Simoni, F., 
Segal, S., Cohen, D. & Givol, D, (1985)j[^82, 1054-1058.
Pfoc- IV/oit- /\c(Uil-5ci'.U6A
Keath, E. J., Caimi, P. G. & Cole, M. D. (1984) Cell 39, 339-348
Kelly, K., Cochran, B. H., Stiles, C. D. & Leder, P. (1983) Cell 
35, 603-610,
Kingston, R. E., Baldwin, A. S. Jr. & Sharp, P. A. (1984)
Nature 312, 280-282.
Klein, G. & Klein, E. (1985) Nature 31L, 190-195.
Knudsen, A. G. (1971) Proc. Nat. Acad. Sci. USA 68, 820-823.
Lachman, H. M. & Skoultchi, A. I. (1984) Nature 310, 592-594.
Lang, J. C. & Spandidos, D. A. (1986) Anticancer Res. 6, 437-450.
Leder, P., Battey, J., Lenoir, G., Moulding, C., Murphy, W.,
Potter, H.,Stewart, T. & Taub, R. (1983) Science 222, 765-771.
Lee, W. F., Schwab, M. , Westaway, D. & Varmus, H. E. ^ 1985)
Mol. Cell. Biol. 5, 3345-3356.
Levy, L. S., Gardner, M. B. & Casey, J. I. (1984) Nature 308, 853-856,
Levy, J. B., Iba, H. & Hanafusa, H. (1986) Proc. Nat. Acad. Sci. USA 
83, 4228-4232.
Li, Y., Holland, C. A., Hartley, J. W. & Hopkins, N. (1984)
Proc- Nat. Acad. Sci- USA 8^, 6808-6811.
Linemeyer, D. L., Menke, J. G., Ruscetti, S. k., Evans, L. H. & 
Scolnick, E, M. (1982) J. Virol. 223-233.
Linial, M. & Groudine, M. (1985) Proc. Nat. Acad. Sci. USA 82, 53-57.
76
Linial, M. Gunderson, N. & Groudine, M. (1985) Science 230, 1126-1132.
Little, C. D., Nau, M. M., Carney, D. N., Gazdar, A. F. & Minna, J. D.
(1983) Nature 306, 194-196.
Lowy, D. R. & Willumsen, B. M. (1986) Cancer Surveys 5, 275-289.
Mackey, L. J., Jarrett, W. F. H., Jarrett, 0. & Laird, H. M. (1972)
J. Nat. Cancer Inst. 16663-1670.
Makino, R., Hayashi, K. & Sugimura, T. (1984) MO. 697-698.
Maniatis, T., Fritsch, E. F. & Sambrook, J. (1982) Laboratory Manual of 
Molecular Cloning, Cold Spring Harbor Publications, New York.
Mann, R., Mulligan, R. C. & Baltimore, D. (1983) Cell 33, 153-159.
Marshall, C. (1985) pp. 487-558, in R. Weiss, N. Teich, H. Varmus &
J. Coffin (eds.), RNA Tumor Viruses, 2nd edition, supplement. Cold 
Spring Harbor Publications, New York.
Martin, G. S. (1970) Nature 227, 1021-1023.
Martin, P., Henry, C., Ferre, F., Duterque-Coquillaud, M., Lagrou, C., 
Ghysdael, J., Debuire, B ., Stehelin, D. & Saule, S. (1986) EMBO. J. 
5, 1529-1533.
Maxam, A. M. & Gilbert, W. (1980) Meths. Enzymol. 65, 499-560.
McGrath, M. S., Pillemer, E ., Kooistra, D. A., Jacobs, S., Jerabek, L.
& Weissman, I. L. (1980) Cold Spring Harbor Symp. Quan. Biol. 
1297-1304.
McLauchlan, J., Gaffney, D., Whitton, J. L. & Clements, J. B (1985) 
Nucleic Acids Res. 1^, 1347-1368.
77
Morse, H. C., Hartley, J.w., Fredrickson, T. N., Yetter, R. A.,
Majumdar, C., Cleveland, J. L. & Rapp, U. R. (1986) Proc. Nat. Acad, 
Sci. USA 83, 6868-6872.
Mount, S. M. (1982) Nucleic Acids Res. 10, 459-472.
Mullins, J. I., Casey, J. W., Nicolson, M. 0. & Davidson, N. (1980) 
Nucleic Acids Res. 8, 3287-3305.
Mullins, J. I., Brody, D. S., Binari, R. C. & Cotter, S. M. (1984) 
Nature 308, 856-858.
Murphree, A. L. & Benedict, W. F. (1984) Science 223, 1028-1033.
Murphy, W., Sarid, J., Taub, R., Vasicek, T., Battey, J., Lenoir, G. &
Leder, P. (1986) Proc. Nat. Acad. Sci. USA 83, 2939-2943.
Naharro, G., Robbins, K.C. & Reddy, E. P. (1984) Science 223, 63-66.
Neel, B. G., Hayward, W. S., Robinson, H. L., Fang, J. & Astrin, S. M.
(1981) Cell 23,323-334.
Neil, J. C., Hughes, D., MacFarlane, R., Wilkie, N. M. , Onions, D. E. , 
Lees, G. & Jarrett, 0. (1984) Nature 308, 814-820.
Neil, J. C. & Onions, D. E. (1985) Anticancer Res. 5, 49-64.
Nilsen, T. W., Maroney, P. A., Goodwin, R. G., Rottman, F. M., 
Crittenden, L. B ., Raines, M. A. & Kung, H-J. (1985) Cell 
41, 719-726.
Noori-Daloii, M. R., Swift, R. A. & Kung, H-J. (1981) Nature 
294, 574-576.
Nottenburg, C. & Varmus, H. E. (1986) Mol. Cell. Biol. 6, 2800-2806.
Nusse, R. (1986) Trends Genet. 2, 244-247.
78
Nusse, R. & Varmus, H. E. (1982) Cell 99-109.
Nusse, R., van Ooyen, A., Cox, D., Fung, Y. K. T. & Varmus, H. E.
(1984) 307, 131-136.
O'Brien, S. J. (1986) Trends Genet. 2, 137-142.
O'Donnell, P. V., Fleissner, E., Lonial, H., Koehne, C. F. & Reicin, A,
(1985) J. Virol. 55, 500-503.
Onions, D. E., Jarrett, 0., Testa, N., Frassoni, F. & Toth, S. (1982) 
Nature 296, 156-158.
Owen, F. L., Strauss, W. M., Murre, C., Duby, A. D., Hiai, H. & 
Seidman, J. G. (1986) Proc. Nat. Acad. Sci. USA 83, 7434-7437.
Papas, T. S. & Lautenberger, J. A. (1985)^318, 237
Notw*
Parnes, J. R. (1986) Trends Genet. 2, 179-183.
Payne, G. S., Courtneidge, S. A., Crittenden, L. B., Fadly, A. M., 
Bishop, J. M. & Varmus, H. E. (1981) Cell 23, 311-322.
Payne, G. S., Bishop, J. M. & Varmus, H. E. (1982) Nature 295, 209-214
Peters, G., Brookes, S., Smith, R. & Dickson, C. (1983) Cell 
33, 369-377.
Peters, G., Lee, A. E. & Dickson, C. (1986) Nature, 320, 628-631.
Piechaczyk, M., Yang, J-Q., Blanchard, J-M., Jeanteur, P. &
Marcu, K. B. (1985) Cell 42, 589-597.
Rabbitts, P. H., Forster, A., Stinson, M. A. & Rabbitts, T. H. (1985) 
EMBO. J. 4, 3727-3733.
79
Rabbitts, T. H., Forster, A., Hamlyn, P. & Baer, R. (1984) Nature 
309, 592-597.
Raines, M. A., Lewis, W. G., Crittenden, L. B. & Kung, H-J. (1985)
Proc. Nat. Acad. Sci. USA 82, 2287-2291.
Rapp, U. R., Cleveland, J. L., Brightman, K., Scott, A. & Ihle, J. N,
(1985) Nature 317, 434-438.
Reddy, E. P., Reynolds, R. K., Watson, D. K., Schultz, R. A.,
Lautenberger, J. & Papas, T. S. (1983) Proc. Nat. Acad. Sci. USA 
80, 2500-2504.
Reed, J. C., Nowell, P. C. & Hoover, R, G. (1985)
Proc. Nat. Acad. Sci. USA 82, 4221-4224.
Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H. &
Schlossman, S. F. (1980) Proc. Nat. Acad. Sci. USA 77, 1588-1592.
Reitsma, P. H., Rothberg, P. G., Astrin, S. M., Trial, J.,,
Bar-Shavit, Z., Hall, A, Teitelbaum, S. L. & Kahn, A. J .  (1983)
Nature 306, 492-494.
Remmers, E. F., Yang, J-Q. & Marcu, K. B. (1986) EMBO, J .  899-904.
Rickard, C. G., Post, J. E., Noronha, F. & Barr, L- (1969) J ,  Nat. 
Cancer Inst. 42, 987-1014.
Robinson, H. L. & Gagnon, G. C .  (1986) J- Virol. 57, 2 8- 36.
Rowley, J. D. (1984) Cancer Res. 3159-3168,
Royer, H. D., Ramali, D., Acuto, 0-, Campen, T. J. & Reinherz, E. L.
(1985) Proc. Nat. Acad. Sci. USA 82, 5510-5514.
Rubin, H. (1980) J. Nat. Cancer Inst, 64, 995-1000,
Ruddon, R. W. (1981) Cancer Biology, Oxford University Press,
Saglio, G. Emanuel, B. S., Guerrasio, A. Giubellino, M. C., Serra, A., 
Lusso, P., Cambrin, G. R., Mazza, U., Malavasi, F., Pegoraro, L. & 
Foa, R. (1985) Cancer Res. 1413-1417.
Saito, H., Hayday, A. C., Wiman, K., Hayward, W. S. & Tonegawa, S. 
(1983) Proc. Nat. Acad. Sci. USA 80, 7476-7480.
Sanger, F. , Coulson, A. R., Barrell, B. G. , Smith, A. J. H. & Roe, B.
(1980) J. Mol. Biol. 143, 161-178.
Selten, G., Cuypers, H. T., Zijlstra, M., Melief, C. & Berns, A. (1984) 
EMBO. J. 3, 3215-3222.
Selten, G. , Cuypers, H. T. & Berns, A. (1985) EMBO. J. 4, 1793-1798.
Selten, G. , Cuypers, H. T., Boelens, W., Robanus-Maandag, E.,
Verbeek, J., Domen, J., van Beveren, C. & Berns, A. (1986) Cell 
603-611.
Shen-Ong, G. L., Morse, H.-'C. ,- Potter, M. & Mushinski, J. F. (1986)
Mol. Cell. Biol. 6, 380-392.
Shibuya, M. , Yokota, J. & Ueyama, Y. (1985) Mol. Cell. Biol.
5, 414-418.
Shih, C-K., Linial, M. , Goodenow, M. M. & Hayward, W. S. (1984)
Proc. Nat. Acad. Sci. USA M ,  4697-4701.
Shima, E. A., Le Beau, M. M., McKeithan, T. W. , Minowada, J.,
Showe, L. C. , Mak, T. K. , Minden, M. D. , Rowley, J. D. & Diaz, M. O.
(1986) Proc. Nat. Acad. Sci. USA 83, 3439-3443.
Showe, L. C., Ballantine, M., Nishikura, K., Erikson, J., Kaji, H. & 
Croce, C. M. (1985) Mol. Cell. Biol. 5, 501-509.
Siebenlist, U., Hennighausen, L., Battey, J. & Leder, P. (1984) Cell 
37, 381-391.
81
Slamon, D. J., deKernion, J. B., Verma, I. M. & Cline, M. J. (1984) 
Science 224, 256-262.
Smith, K. A. (1985) Cancer Cells 3, 205-210.
Soe, L. H. & Roy-Burman, P. (1984) Gene 31, 123-128.
Southern, E. (1975) J. Mol. Biol. 98, 503-517.
Stanton, L. W., Fahrlander, P. D., Tesser, P. M. & Marcu, K. B. (1984) 
Nature 310, 423-425.
Stanton, L. W., Schwab, M. & Bishop, J. M. (1986) Proc. Nat. Acad.
Sci. USA 83, 1772-1776.
Steffen, D. (1984) Proc. Nat. Acad. Sci. USA 81, 2097-2101.
Stehelin, D. , Varmus, H. E., Bishop, J. M. & Vogt, P. K. (1976) Nature 
260, 170-173.
Stewart, M. A. (1983) Ph.D. Thesis, Glasgow University.
Stewart, M. A., Warnock, M., Wheeler, A., Wilkie, N. M. ,
Mullins, J. I., Onions, D. E. & Neil, J. C. (1986a) J. Virol.
58, 825-834.
Stewart, M. A., Forrest, D., MacFarlane, R., Onions, D., Wilkie, N. M. 
& Neil, J. C. (1986b) Virol. 1^, 121-134.
A- R ' A 5c:<!re.<t TJAy 7(0.
Stewart, T. A., Pattengale, P. K. & Leder, P. (1984b) Cell 18, 627-637
Stiles, C. D., Capone, G. T., Scher, C. D., Antoniades, H. N.,
Van Wyk, J. J. & Pledger, W. J. (1979) Proc. Nat. Acad. Sci. USA
76, 1279-1283.
Sumegi, J., Spira, J., Bazin, H., Szpirer, J., Levan, G. & Klein, G. 
(1983) Nature 306, 497-498.
82
Swanstrom, R., Parker, R. C., Varmus, H. E. & Bishop, J. M. (1983)
Proc. Nat. Acad. Sci. USA 80, 2519-2523.
Swift, R. A., Shaller, E., Witter, R. L. & Kung, H-J. (1985) J. Virol. 
M ,  869-872.
Taub, R., Moulding, C., Battey, J., Murphy, W., Vasicek, T., Lenoir, G. 
& Leder, P. (1984a) Cell 36, 339-348.
Taub, R., Kelly. K., Battey, J., Latt, S., Lenoir, G., Tantrahavi, U., 
Tu, Z. & Leder, P. (1984b) Cell 37, 511-520.
Teich, N. , Wyke, J. & Kaplan, P. (1985) pp. 187-248, in R. Weiss,
N. Teich, H. Varmus & J. Coffin (eds.) RNA Tumor Viruses,
2nd edition, supplement. Cold Spring Harbor Laboratory, New York.
Temin, H. (1976) Science 1^, 1075-1080.
Temin, H. (1980) Cell 599-600.
Theilen, G. H. , Kawakami, T. G., Rush, J. D. & Munn, R. J. (1969) 
Nature 222, 589-590.
Thompson, C. B. , Challoner, P. B., Neiman, P. E. & Groudine, M. (1985) 
Nature 314, 363-366.
Toyoshima, K. & Vogt, P. K. (1969) Virol. 3^, 930-931.
Trent, U ., Meltzer, P ., Rosenblum, M., Harsh, G., Kinzler, K.,
Mashal, R., Feinberg, A. & Vogelstein, B. (1986) Proc. Nat. Acad. 
Sci. USA 83, 470-473.
Tsichlis, P. N., Strauss, P. G. & Hu, L. F . (1983) Nature 302, 445-449.
Tsichlis, P. N., Strauss, P. G. & Lohse, M. A. (1985) J. Virol.
56, 258-267.
83
Van Beveren, C., Coffin, J., Hughes, S. (1985) pp.567-1148, in
R. Weiss, N. Teich, H. Varmus & J. Coffin (eds.) RNA Tumor Viruses, 
2nd edition, supplement. Cold Spring Harbor Laboratory, New York.
van Beneden, R. J., Watson, D. K., Chen, T. T., Lautenberger, J. A. & 
Papas, T. S. (1986) Proc. Nat. Acad. Sci. USA 83, 3698-3702.
van der Putten, H., Quint, W., van Raaj, J., Maandag, E. R.,
Verma, I. M. & Berns, A. (1979)^^, 729-739.
Cel]
Voronova, A. F. & Sefton, B. M. (1986) Nature 319, 682-685.
Waldman, T. A. (1986) Science 232, 727-732.
Walther, N., Jansen, H. W., Trachman, C. & Bister, K. (1986) Virol. 
154, 219-223.
Watson, D. K., Reddy, E. P., Duesberg, P. H. & Papas, T. S. (1983) 
Proc. Nat. Acad. Sci. USA 80, 2146-2150.
Watt, R., Stanton, L. W., Marcu, K. B., Gallo, R. C., Croce, C. M. & 
Rovera, G. (1983a) Nature 303, 725—728.-
Watt, R., Nishikura, K., Sorrentino, J., ar-Rushdi, A., Croce, C. M. & 
Rovera, G. (1983b) Proc. Nat. Acad. Sci. USA 6307-6311.
Watt, R. A., Shatzman, A. R. & Rosenberg, M. (1985) Mol. Cell. Biol.
5, 448-456.
Weinberg, R. A. (1985) Science 2^, 770-776.
Weiss, R. , Teich, N., Varmus H. & Coffin, J. (1982) RNA Tumor Viruses, 
Cold Spring Harbor Laboratory, New York.
Westaway, D., Payne, G . & Varmus, H . E . (1984) Proc. Nat. Acad.
Sci. USA 81, 843-847.
84
Westaway, D., Papkoff, J., Moscovici, C. & Varmus, H. E. (1986) 
EMBO. J. 5, 301-309.
Wiman, K. , Clarkson, B., Hayday, A., Saito, H., Tonegawa, S. & 
Hayward, W. S. (1984) Proc. Nat. Acad. Sci. USA 6798-6802.
Yang, J-Q., Bauer, S. R., Mushinski, J. F. & Marcu, K. B. (1985) 
EMBO. J. 4, 1441-1447.
S.^ Tvuker^  «^-ncUrMn, Kaytl, Co»tvipUli^  H-D. X Y«un^  NaWc
Yoshikai, Y., Anatoniou, A., Clark, S. P., Yanagi, Y., Sanster, R. ,
Elsen, P., Terhorst, C. & Mak, T. N. (1984) Nature 312, 521-524.
85
